Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 22:15:24 Desc Main Document Page 1 01 03

IN THE UNITED STATES BANKRUPTCY COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION

In re:

EIGER BIOPHARMACEUTICALS, INC., et al. 1

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

STATEMENT OF FINANCIAL AFFAIRS OF DEBTOR EIGER BIOPHARMACEUTICALS, INC. (CASE NO. 24-80040)

The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Avenue, Dallas, Texas 75201.



IN THE UNITED STATES BANKRUPTCY COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION

In re:

EIGER BIOPHARMACEUTICALS, INC., et al. 1

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY, AND DISCLAIMERS REGARDING THE DEBTORS' SCHEDULES OF ASSETS AND LIABILITIES AND STATEMENTS OF FINANCIAL AFFAIRS

On April 1, 2024 (the "<u>Petition Date</u>"), Eiger BioPharmaceuticals, Inc. and its affiliated debtors in the above-captioned chapter 11 cases (each a "<u>Debtor</u>" and, collectively, the "<u>Debtors</u>") commenced voluntary cases (the "<u>Chapter 11 Cases</u>") under chapter 11 of title 11, United States Code, §§ 101 *et seq.* (the "<u>Bankruptcy Code</u>") in the United States Bankruptcy Court for the Northern District of Texas (the "<u>Court</u>").

The Debtors continue to operate their businesses and manage their properties as debtors and debtors in possession, pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. The Chapter 11 Cases have been consolidated for procedural purposes only and are being jointly administered under case number 24-80040 (SGJ).

The Schedules of Assets and Liabilities (the "Schedules") and Statements of Financial Affairs (the "Statements") were prepared pursuant to section 521 of the Bankruptcy Code and Rule 1007 of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules") by management of the Debtors with unaudited information available as of the Petition Date.

These Global Notes and Statement of Limitations, Methodology, and Disclaimers Regarding the Debtors' Schedules and Statements of Financial Affairs (the "Global Notes") are incorporated by reference in, and comprise an integral part of, each Debtor's respective Schedules and Statements, and should be referred to and considered in connection with any review of the Schedules and Statements.

In preparing the Schedules and Statements, the Debtors relied on financial data derived from their books and records that was available at the time of such preparation. The Debtors, and

The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Avenue, Dallas, Texas 75201.

their agents, attorneys, and advisors do not guarantee or warrant the accuracy or completeness of the data that is provided herein, and shall not be liable for any loss or injury arising out of or caused in whole or in part by the acts, errors, or omissions, whether negligent or otherwise, in procuring, compiling, collecting, interpreting, reporting, communicating, or delivering the information contained herein. While reasonable efforts have been made to provide accurate and complete information herein, inadvertent errors or omissions may exist. The Debtors reserve their rights to amend and supplement the Schedules and Statements as may be necessary or appropriate. For the avoidance of doubt, the Debtors and their agents, attorneys, and advisors expressly do not undertake any obligation to update, modify, revise, or re-categorize the information provided herein, or to notify any third party should the information be updated, modified, revised, or re-categorized, except as required by applicable law. In no event shall the Debtors, or their agents, attorneys, and advisors, be liable to any third party for any direct, indirect, incidental, consequential, or special damages (including, but not limited to, damages arising from the disallowance of a potential claim against the Debtors or damages to business reputation, lost business, or lost profits), whether foreseeable or not and however caused, even if the Debtors or their agents, attorneys, or advisors are advised of the possibility of such damages.

Given, among other things, the uncertainty surrounding the valuation and nature of certain assets and liabilities, to the extent that a Debtor shows more assets than liabilities, this is not an admission that such Debtor was solvent on the Petition Date or at any time prior to the Petition Date. Likewise, to the extent that a Debtor shows more liabilities than assets, it is not an admission that such Debtor was insolvent on the Petition Date or any time prior to the Petition Date.

Douglas Staut has signed each set of the Schedules and Statements. Mr. Staut serves as the Chief Restructuring Officer ("CRO") of the Debtors, and he is an authorized signatory for each of the Debtors in these Chapter 11 Cases. In reviewing and signing the Schedules and Statements, Mr. Staut has necessarily relied upon the efforts, statements, advice, and representations of the Debtors and their advisors. Mr. Staut has not (and could not have) personally verified the accuracy of each such statement and representation, including statements and representations concerning amounts owed to creditors, classification of such amounts, and creditor addresses.

Global Notes and Overview of Methodology

- 1. In the ordinary course of business, the Debtors routinely engage in intercompany transactions (collectively, the "Intercompany Transactions") with one another, which result in intercompany receivables and payables (collectively, the "Intercompany Claims"). Intercompany Transactions and Intercompany Claims arise from relationships and historical practice, or certain intercompany agreements and intercompany loans (collectively, the "Intercompany Relationships" or "Intercompany Agreements") to support operations and shared service functions, including product development services, software sales, software licensing, provision of management services, revenue sharing arrangements, back-office support transactions and intercompany loan and interest payments. The Debtors manually track and allocate receivables and payables across the corporate enterprise.
- 2. **EB Pharma LLC.** EB Pharma LLC ("<u>EB Pharma</u>") is a wholly-owned subsidiary of Eiger BioPharmaceuticals, Inc. ("<u>Eiger</u>"), which is the primary operating entity. EB Pharma had no operations in the year prior to the Petition Date other than tax filings. EB Pharma has no

sales receipts. All vendors supporting its tax filings are paid by Eiger. Accordingly, the Debtors have reported the only assets owned by EB Pharma, which includes licenses and interests in insurance policies. The Debtors reserve all rights to amend and supplement the Schedules and Statements as may be necessary or appropriate.

- 3. <u>Eiger BioPharmaceuticals Europe Limited</u>. Eiger BioPharmaceuticals Europe Limited ("<u>Eiger BioPharmaceuticals Europe</u>") is a wholly-owned subsidiary of Eiger. Eiger BioPharmaceuticals Europe had no operations in the year prior to the Petition Date other than tax filings. Eiger BioPharmaceuticals Europe has no sales receipts. All vendors supporting its tax filings are paid by Eiger. The Debtors reserve all rights to amend and supplement the Schedules and Statements as may be necessary or appropriate.
- 4. <u>EBPI Merger Inc.</u> EBPI Merger Inc. ("<u>EBPI Merger</u>") is a wholly-owned subsidiary of Eiger. EBPI Merger had no operations in the year prior to the Petition Date other than tax filings. EBPI Merger has no sales receipts. Tax liabilities for EBPI Merger are paid through Eiger's operating accounts. Accordingly, the Debtors have reported the only assets owned by EBPI Merger, which includes intellectual property and interests in insurance policies or annuities. The Debtors reserve all rights to amend and supplement the Schedules and Statements as may be necessary or appropriate.
- 5. <u>EigerBio Europe Limited</u>. EigerBio Europe Limited ("<u>EigerBio Europe</u>") is a wholly-owned subsidiary of Eiger. EigerBio Europe incurs rent and other operating expenses. Cash collections from any sales in Germany are deposited into EigerBio Europe's bank account. The Debtors have reported the assets owned by EigerBio Europe. The Debtors reserve all rights to amend and supplement the Schedules and Statements as may be necessary or appropriate.
- 6. Reservations and Limitations. Reasonable efforts have been made to prepare and file complete and accurate Schedules and Statements; however, as noted above, inadvertent errors or omissions may exist. The Debtors reserve all rights to amend and supplement the Schedules and Statements as may be necessary or appropriate. Nothing contained in the Schedules and Statements constitutes a waiver of any of the Debtors' rights or an admission of any kind with respect to these Chapter 11 Cases, including, but not limited to, any rights or claims of the Debtors against any third party or issues involving substantive consolidation, equitable subordination, or defenses or causes of action arising under the provisions of chapter 5 of the Bankruptcy Code or any other relevant applicable bankruptcy or non-bankruptcy laws to recover assets or avoid transfers. Any specific reservation of rights contained elsewhere in the Global Notes does not limit in any respect the general reservation of rights contained in this paragraph.
 - (a) **No Admission.** Nothing contained in the Schedules and Statements is intended or should be construed as an admission or stipulation of the validity of any claim against the Debtors, any assertion made therein or herein, or a waiver of the Debtors' rights to dispute any claim or assert any cause of action or defense against any party.
 - (b) **Recharacterization.** Notwithstanding that the Debtors have made reasonable efforts to correctly characterize, classify, categorize, or designate certain claims, assets, executory contracts, unexpired leases, and other items reported in the

Schedules and Statements, the Debtors nonetheless may have improperly characterized, classified, categorized, or designated certain items. The Debtors reserve all rights to recharacterize, reclassify, recategorize, or redesignate items reported in the Schedules and Statements at a later time as is necessary and appropriate, including, without limitation, whether contracts or leases listed herein were deemed executory or unexpired as of the Petition Date and remain executory and unexpired post-petition. Disclosure of information in one or more Schedules, Statements, or one or more exhibits or attachments thereto, even if incorrectly placed, shall be deemed to be disclosed in the correct Schedules, Statements, exhibits, or attachments.

- (c) Classifications. Listing (i) a claim on Schedule D as "secured," (ii) a claim on Schedule E/F as "priority" or "unsecured," or (iii) a contract on Schedule G as "executory" or "unexpired" does not constitute an admission by the Debtors of the legal rights of the claimant or contract counterparty, or a waiver of the Debtors' rights to recharacterize or reclassify such claim or contract or to setoff such claim.
- (d) Claims Description. Any failure to designate a claim on the Debtors' Schedules and Statements as "disputed," "contingent," or "unliquidated" does not constitute an admission by the Debtors that such amount is not "disputed," "contingent," or "unliquidated." Each Debtor reserves all rights to dispute, or assert offsets or defenses to, any claim reflected on its respective Schedules and Statements on any grounds, including, without limitation, liability, or classification, or to otherwise subsequently designate such claims as "disputed," "contingent," or "unliquidated" or object to the extent, validity, enforceability, or priority of any claim. Moreover, listing a claim does not constitute an admission of liability by the Debtors against which the claim is listed or by any of the Debtors. The Debtors reserve all rights to amend their Schedules and Statements as necessary and appropriate, including, but not limited to, with respect to claim description and designation.
- (e) **Estimates and Assumptions.** The preparation of the Schedules and Statements required the Debtors to make reasonable estimates and assumptions with respect to the reported amounts of assets and liabilities, the amount of contingent assets and contingent liabilities on the Schedules and Statements, and the reported amounts of revenues and expenses during the applicable reporting periods. Actual results could differ from such estimates.
- (f) Causes of Action. Despite reasonable efforts, the Debtors may not have identified all current and potential causes of action the Debtors may have against third parties in their respective Schedules and Statements, including, without limitation, avoidance actions arising under chapter 5 of the Bankruptcy Code and actions under other relevant bankruptcy and non-bankruptcy laws to recover assets. The Debtors reserve all rights with respect to any causes of action, and nothing in these Global Notes or the Schedules and Statements should be construed as a waiver of any such causes of action.

- (g) Intellectual Property Rights. Exclusion of certain intellectual property from the Schedules and Statements should not be construed as an admission that such intellectual property rights have been abandoned, have been terminated or otherwise expired by their terms, or have been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction. Conversely, inclusion of certain intellectual property rights in the Schedules and Statements should not be construed as an admission that such intellectual property rights have not been abandoned, have not been terminated or otherwise expired by their terms, or have not been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction.
- (h) Executory Contracts and Unexpired Leases. Although the Debtors made diligent efforts to identify contracts and unexpired leases as executory within the scope of section 365 of the Bankruptcy Code and to attribute an executory contract to its rightful Debtors, in certain instances, the Debtors may have inadvertently failed to do so due to the complexity and size of the Debtors' businesses. Accordingly, the Debtors reserve all of their rights with respect to the inclusion or exclusion of executory contracts and unexpired leases, as well as the named parties to any and all executory contracts and unexpired leases, including the right to amend Schedule G at any time during the pendency of these Chapter 11 Cases.
- (i) **Insiders.** In the circumstance where the Schedules and Statements require information regarding "insiders," the Debtors have included information with respect to certain individuals who served as officers and directors, as the case may be, during the relevant time periods. Such individuals may no longer serve in such capacities.

The listing or omission of a party as an insider for purposes of the Schedules and Statements is not intended to be, nor should it be, construed as an admission of any fact, right, claim, or defense and all such rights, claims, and defenses are hereby expressly reserved. Information regarding the individuals listed as insiders in the Schedules and Statements has been included for informational purposes only and such information may not be used for: (i) the purposes of determining (A) control of the Debtors; (B) the extent to which any individual exercised management responsibilities or functions; (C) corporate decision-making authority over the Debtors; or (D) whether such individual could successfully argue that he or she is not an insider under applicable law, including the Bankruptcy Code and federal securities laws, or with respect to any theories of liability or (ii) any other purpose.

- 7. <u>Description of Cases and "As Of" Information Date</u>. On April 1, 2024, or the Petition Date, each of the Debtors filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code in the Court. The Debtors continue to operate their business. The information provided herein, except as otherwise noted, is reported as of the Petition Date of each respective Debtor, as appropriate.
- 8. **Methodology.**

- (a) **Basis of Presentation.** The Schedules and Statements do not purport to represent financial statements prepared in accordance with Generally Accepted Accounting Principles in the United States ("GAAP") nor are they intended to be fully reconciled to the financial statements of each Debtor. The Schedules and Statements contain unaudited information that is subject to further review and potential adjustment. The Schedules and Statements reflect the Debtors' reasonable efforts to report the assets and liabilities of each Debtor on an unconsolidated basis.
- (b) **Duplication.** Certain of the Debtors' assets, liabilities, and prepetition payments may properly be disclosed in multiple parts of the Statements and Schedules. To the extent these disclosures would be duplicative, the Debtors have endeavored to only list such assets, liabilities, and prepetition payments once.
- (c) Net Book Value. In certain instances, current market valuations for individual items of property and other assets are neither maintained by, nor readily available to the Debtors. Accordingly, unless otherwise indicated, the Debtors' Schedules and Statements reflect net book values as of the Petition Date. Market values may vary, in some instances, materially, from net book values. The Debtors believe that it would be an inefficient use of estate assets for the Debtors to obtain the current market values of their property. Accordingly, the Debtors have indicated in the Schedules and Statements that the market values of certain assets and liabilities are undetermined. Also, assets that have been fully depreciated or that were expensed for accounting purposes either do not appear in these Schedules and Statements, or are listed with a zero-dollar value, as such assets have no net book value. The omission of an asset from the Schedules and Statements does not constitute a representation regarding the ownership of such asset, and any such omission does not constitute a waiver of any rights of the Debtors with respect to such asset.
- (d) **Undetermined Amounts.** The description of an amount as "unknown," "TBD," or "undetermined" is not intended to reflect upon the materiality of such amount.
- (e) **Unliquidated Amounts.** Amounts that could not be fairly quantified by the Debtors are scheduled as "unliquidated."
- (f) **Totals.** All totals that are included in the Schedules and Statements represent totals of all known amounts. To the extent there are unknown or undetermined amounts, the actual total may be different from the listed total.
- (g) Paid Claims. The Debtors have authority to pay certain outstanding prepetition payables pursuant to various orders entered by the Court. The Debtors scheduled such amounts as of the Petition Date and noted such amounts as contingent. To the extent the Debtors later pay any amount of the claims listed in the Schedules and Statements pursuant to any orders entered by the Court, the Debtors reserve all rights to amend or supplement the Schedules and Statements or to take other action, such as filing claims objections, as is necessary and appropriate to avoid overpayment or duplicate payments for liabilities. Nothing contained herein should

- be deemed to alter the rights of any party in interest to contest a payment made pursuant to an order of the Court where such order preserves the right to contest.
- (h) **Liens.** The inventories, property, and equipment listed in the Schedules and Statements are presented without consideration of any liens.
- (i) **Currency.** Unless otherwise indicated, all amounts are reflected in U.S. dollars. Some bank accounts in EigerBio Europe may be held in Euro but converted to the U.S. Dollar equivalent as of the Petition Date.
- (j) **Liabilities.** The Debtors have sought to allocate liabilities between the prepetition and postpetition periods based on the information and research conducted in connection with the preparation of the Schedules and Statements. As additional information becomes available and further research is conducted, the allocation of liabilities between the prepetition and postpetition periods may change. The Debtors reserve the right to amend the Schedules and Statements as they deem appropriate in this and all other regards.
- (k) Excluded Assets and Liabilities. The Debtors have excluded certain categories of assets and liabilities from the Schedules and Statements, including, but not limited to: certain deferred charges, investments in subsidiaries, reserves recorded only for purposes of complying with the requirements of GAAP, and deferred tax assets, and deferred tax liabilities. The Debtors have also excluded rejection damage claims of counterparties to executory contracts and unexpired leases that may or may not be rejected, to the extent such damage claims exist. Other immaterial assets and liabilities may also have been excluded.
- (l) Credits and Adjustments. The claims of individual creditors for, among other things, goods, products, services, or taxes are listed as the amounts entered on the Debtors' books and records and may either (i) not reflect credits, allowances, or other adjustments due from such creditors to the Debtors or (ii) be net of accrued credits, allowances, or other adjustments that are actually owed by a creditor to the Debtors on a postpetition basis on account of such credits, allowances, or other adjustments earned from prepetition payments and critical vendor payments, if applicable. The Debtors reserve all of their rights with regard to such credits, allowances, or other adjustments, including, but not limited to, the right to modify the Schedules, assert claims objections and/or setoffs with respect to the same, or apply such allowances in the ordinary course of business on a postpetition basis.
- (m) **Setoffs.** The Debtors may periodically incur setoffs and net payments in the ordinary course of business. Such setoffs and nettings may occur due to a variety of transactions or disputes. Although such setoffs and other similar rights may have been accounted for when scheduling certain amounts, these ordinary course setoffs are not independently accounted for, and as such, are or may be excluded from the Debtors' Schedules and Statements. The Debtors reserve all rights to challenge any setoff and/or recoupment rights that may be asserted.

9. <u>Global Notes Control.</u> These Global Notes pertain to and comprise an integral part of each of the Schedules and Statements and should be referenced in connection with any review thereof. In the event that the Schedules and Statements conflict with these Global Notes, these Global Notes shall control.

10. Specific Schedules Disclosures.

- (a) <u>Schedules Summary</u>. Except as otherwise noted, the asset totals represent amounts as of the Petition Date and liability information provided herein represents the Debtors' liabilities as of the Petition Date.
- (b) Schedule A/B, Part 4 Investments; Non-Publicly Traded Stock and Interests in Incorporated and Unincorporated Businesses, including any Interest in an LLC, Partnership, or Joint Venture. Eiger's ownership interests in subsidiaries have been listed in Schedule A/B, Part 4, as undetermined amounts on account of the fact that the fair market value of such ownership is dependent on numerous variables and factors, and may differ significantly from their net book value.
- (c) Schedule A/B, Part 5 Inventory. The Debtors' products have three- or four-year shelf lives. The Debtors' inventory is managed by third parties.
- (d) Schedule A/B, Part 7 Office furniture, fixtures, and equipment; and collectibles. The Debtors have used book values as of April 1, 2024 for reporting office furniture and equipment. There have been no valuations on any of such assets. These amounts may include leasehold improvements. The Debtors reserve all of their rights to re-categorize and/or re-characterize such asset holdings to the extent the Debtors determine that such holdings were improperly listed.
- (e) Schedule A/B, Part 9 Real Property. The Debtors lease all of their real properties and, as such, the leased properties' value have been marked as undetermined. Furthermore, certain of the property leases reflected on Schedule A/B 55 may contain renewal options, guarantees of payment, options to purchase, rights of first refusal, rights to lease additional lands, and other miscellaneous rights. Such rights, powers, duties, and obligations are not separately set forth on Schedule A/B 55. The Debtors hereby expressly reserve the right to assert that any instrument listed on Schedule A/B 55 is an executory contract or unexpired lease within the meaning of section 365 of the Bankruptcy Code. The Debtors reserve all of their rights, claims, and causes of action with respect to claims associated with any contracts and agreements listed on Schedule A/B 55, including their right to dispute or challenge the characterization or the structure of any transaction, document, or instrument, including any intercompany agreement.
- (f) Schedule A/B, Part 10 Intangibles and Intellectual Property. The value of the Debtors' intangible assets is listed as undetermined. The Debtors are not able to provide a schedule with values specific to its intellectual property (including but not limited to, patents, trademarks, internet domains, and licenses).

- (g) Schedule A/B, Part 11 All Other Assets. Eiger has incurred significant net operating losses ("NOLs") and research and development credits ("R&D Credits") (together, the "Tax Attributes") since its inception. As of December 31, 2023, Eiger has generated federal NOLs of \$322.5 million. The Debtors also has \$47.1 million of state NOLs, \$15.5 million of federal orphan drug tax credits, \$4.0 million of state R&D Credits and \$1.6 million of federal R&D Credits. Further, the Debtors estimate that they may generate additional Tax Attributes in the 2024 tax year. Such Tax Attributes have not been valued as of the Petition Date and may be restricted in their use.
- (h) Schedule D Creditors Who Have Claims Secured by Property. The Debtors have made reasonable efforts to report all secured claims against the Debtors on Schedule D based on the Debtors' books and records as of the Petition Date. However, the actual value of claims against the Debtors may vary significantly from the represented liabilities. Parties in interest should not accept that the listed liabilities necessarily reflect the correct amount of any secured creditor's allowed claims or the correct amount of all secured claims. Similarly, parties in interest should not anticipate that recoveries in these cases will reflect the relationship of the aggregate asset values and aggregate liabilities set forth in the Schedules. Parties in interest should consult their own professionals and advisors with respect to pursuing a claim. Although the Debtors and their professionals have generated financial information and data the Debtors believe to be reasonable, actual liabilities (and assets) may deviate significantly from the Schedules due to certain events that occur throughout these Chapter 11 Cases.

Except as specifically stated herein, lessors of real property and equipment, utility companies, and any other parties which may hold security deposits or other security interests, have not been listed on Schedule D. The Debtors have also not listed on Schedule D any parties whose claims may be secured through rights of setoff, deposits, or advance payments.

Although the Debtors may have scheduled claims of various creditors as secured claims, the Debtors reserve all rights to dispute or challenge the secured nature of any creditor's claim or the characterization of the structure of any transaction or any document or instrument (including, without limitation, any intercompany agreement) related to such creditor's claim (except as otherwise agreed to or stated pursuant to a stipulation, agreed order, or general order entered by the Bankruptcy Court that is or becomes final). The Debtors have not included on Schedule D the claims of any parties that may believe their claims are secured through setoff rights or inchoate statutory lien rights.

The descriptions provided on Schedule D are intended only as a summary. Reference to the applicable loan agreements and related documents is necessary for a complete description of the collateral and the nature, extent, and priority of any liens. Nothing in these Global Notes or in the Schedules and Statements shall be deemed a modification, interpretation, or an acknowledgment of the terms of such agreements or related documents.

(i) Schedule E/F – Creditors Who Have Unsecured Claims.

The Debtors have made reasonable efforts to report all priority and general unsecured claims against the Debtors on Schedule E/F based on the Debtors' books and records as of the Petition Date. However, the actual value of claims against the Debtors may vary significantly from the represented liabilities. Certain claims on E/F may have been satisfied post-petition by the Debtors (including employee wages in the ordinary course) or third parties. Furthermore, accrued interest for some claims may not have been possible to determine. Parties in interest should not accept that the listed liabilities necessarily reflect the correct amount of any unsecured creditor's allowed claims or the correct amount of all unsecured claims. Similarly, parties in interest should not anticipate that recoveries in these cases will reflect the relationship of the aggregate asset values and aggregate liabilities set forth in the Schedules. Parties in interest should consult their own professionals and advisors with respect to pursuing a claim. Although the Debtors and their professionals have generated financial information and data the Debtors believe to be reasonable, actual liabilities (and assets) may deviate significantly from the Schedules due to certain events that occur throughout these Chapter 11 Cases.

The claims listed on Schedule E/F arose or were incurred on various dates. In certain instances, the date on which a claim arose may be unknown or subject to dispute. Although reasonable efforts have been made to determine the date upon which claims listed in Schedule E/F were incurred or arose, updating that date for each claim in Schedule E/F would be unduly burdensome and cost-prohibitive and, therefore, the Debtors have not listed a date for each claim listed on Schedule E/F.

In the ordinary course of business, the Debtors generally receive invoices for goods and services after the delivery of such goods or services. As of the filing of the Schedules and Statements, the Debtors may not have received all invoices for payables, expenses, or liabilities that may have accrued before the Petition Date. Furthermore, payments to vendors and lienholders made subsequent to the filing of these Schedules will not be reflected in these Schedules. The Debtors reserve the right, but are not required, to amend Schedules E/F if they receive such invoices and/or make such payments. The claims of individual creditors are generally listed at the amounts recorded on the Debtors' books and records and may not reflect all credits or allowances due from the creditor. The Debtors reserve all of their rights concerning credits or allowances.

Part 1 - Creditors with Priority Unsecured Claims. The Debtors included certain claims related to severance. The Debtors also included certain claims owing to various taxing authorities to which the Debtors may be liable. Priority unsecured tax claims are listed as contingent since they have been paid through first day relief.

Moreover, the inclusion of any amounts owed to taxing authorities does not constitute an admission by the Debtors of such liability.

The Debtors reserve the right to assert that any claim listed on Schedule E/F does not constitute a priority claim under the Bankruptcy Code.

Part 2 - Creditors with Nonpriority Unsecured Claims. The Debtors have used reasonable efforts to report all general unsecured claims against the Debtors in Schedule E/F, Part 2, based upon the Debtors' books and records as of the Petition Date. The Debtors made a reasonable attempt to set forth their unsecured obligations, although the actual amount of claims against the Debtors may vary from those liabilities represented on Schedule E/F, Part 2. The listed liabilities, which have been listed on a gross accounts payable basis, may not reflect the correct amount of any unsecured creditor's allowed claims or the correct amount of all unsecured claims.

Schedule E/F, Part 2, reflects certain prepetition amounts owing to counterparties to executory contracts and unexpired leases. Such prepetition amounts, however, may be paid in connection with the assumption or assumption and assignment of an executory contract or unexpired lease. Prepetition amounts that may be paid in accordance with court orders, are marked as contingent. In addition, Schedule E/F, Part 2, does not include claims that may arise in connection with the rejection of any executory contracts and unexpired leases, if any, that may be or have been rejected.

reserve all rights to dispute the validity, status, or enforceability of any contracts, agreements or leases set forth in Schedule G and to amend or supplement Schedule G as necessary. Additionally, the placing of a contract or lease onto Schedule G shall not be deemed an admission that such contract is an executory contract or unexpired lease, or that it is necessarily a binding, valid, and enforceable contract. Any and all of the Debtors' rights, claims and causes of action with respect to the contracts and agreements listed on Schedule G are hereby reserved and preserved. In addition, the Debtors are continuing their review of all relevant documents and expressly reserve their right to amend all Schedules at a later time as necessary and/or to challenge the classification of any agreement as an executory contract or unexpired lease in any appropriate filing.

The names of employees and consultants and other individuals have been redacted for privacy purposes.

Certain information, such as the contact information or addresses of the counterparty, may not be included where such information could not be obtained using the Debtors' reasonable efforts. Listing a contract or agreement on Schedule G does not constitute an admission that such contract or agreement is an executory contract or unexpired lease or that such contract or agreement was in effect on the Petition Date or is valid or enforceable. Expired contracts and leases may have also

been inadvertently included. The Debtors hereby reserve all of their rights to dispute the validity, status, or enforceability of any contracts, agreements, or leases set forth in Schedule G and to amend or supplement such Schedule as necessary.

Certain of the leases and contracts listed on Schedule G may contain renewal options, guarantees of payment, indemnifications, options to purchase, rights of first refusal and other miscellaneous rights. Such rights, powers, duties, and obligations are not set forth separately on Schedule G. In addition, the Debtors may have entered into various other types of agreements in the ordinary course of their business, such as supplemental agreements and letter agreements, which documents may not be set forth in Schedule G. The Debtors reserve the right to dispute the effectiveness of any such contract listed on Schedule G or to amend Schedule G at any time to remove any contract.

The Debtors have reserved all rights to dispute or challenge the characterization of any transaction or any document or instrument related to a creditor's claim.

Although the Debtors have made diligent attempts to attribute an executory contract to its rightful Debtor, in certain instances, the Debtors may have inadvertently failed to do so due to the complexity and size of the Debtors' businesses. Accordingly, the Debtors reserve all of its rights with respect to the named parties of any and all executory contracts, including the right to amend Schedule G.

Omission of a contract or agreement from Schedule G does not constitute an admission that such omitted contract or agreement is not an executory contract or unexpired lease. The Debtors' rights under the Bankruptcy Code with respect to any such omitted contract or agreement is not impaired by the omission. Certain Debtors are guarantors and parties to guaranty agreements regarding the Debtors' prepetition credit facility. The guaranty obligations arising under these agreements are reflected on Schedules D and F only.

11. Specific Statements Disclosures.

(a) Statements, Part 1, Question 1 – Gross Revenue from business. The Debtors recognize GAAP revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. The Debtors recognize product revenue when a customer obtains control of the Debtors' product, which occurs at a point in time, typically upon delivery to a customer as the delivery of the product is the only performance obligation.

The product is distributed through an exclusive third-party logistics, or 3PL, distribution agent that does not take title to the product. The 3PL distributes Zokinvy to the customers, specialty pharmacies and specialty distributors (collectively referred to as "customers"), who then distribute the product to

healthcare providers and patients. Taxes collected from the customer relating to product sales and remitted to governmental authorities are excluded from revenue.

Revenues from product sales are recorded at the net sales price, or the transaction price, which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, co-pay assistance, chargebacks, rebates, and other allowances that are offered within contracts between us and customers, healthcare providers and other indirect customers relating to the sale of Zokinvy. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect best estimates of the amount of consideration to which the Debtors are entitled based on the terms of the contract.

The components of variable consideration related to product revenue were detailed in the *Debtors' Emergency Motion for Entry of Interim and Final Orders* (I) Authorizing the Debtors to Honor and Continue Certain Customer Programs and Customer Obligations in the Ordinary Course of Business, and (II) Authorizing Banks to Honor and Process Checks and Electronic Transfer Requests Related Thereto [Docket No. 17] and are customary in the pharmaceutical industry.

- (b) Statements, Part 2, Question 4 Payments and Transfers to Certain Insiders within 1 year before the filing. The Debtors reported payments to non-officer and officer insiders within the year prior to the Petition Date. Out of an abundance of caution, payments made to Alvarez & Marsal are reported both on Statements Question 4 and Question 11 due to the firm's relationship to the Debtors as Chief Restructuring Officer. Payments made to Danforth Advisors LLC are also included out of an abundance of caution due to the Chief Financial Officer's involvement with the company. Payments made to Eiger Group International, Inc. are also included out of an abundance of caution due to a former Director's involvement with the company. The Debtors reserve all rights with respect to the determination or status of a person as an "insider" as defined in section 101(13) of the Bankruptcy Code.
- (c) Statements, Part 3, Question 7 Legal Actions or Assignments. The Debtors have made reasonable best efforts to identify all current pending litigation and legal proceedings involving the Debtors. The Debtors reserve all of their rights and defenses with respect to any and all listed lawsuits and legal proceedings. The listing of such suits and proceedings shall not constitute an admission by the Debtors of any liabilities or that the actions or proceedings were correctly filed against the Debtors.

- (d) Statements, Part 4, Question 9 Gifts or Charitable Contributions within 2 years before the filing. Research grants are not considered in the context of this question. Research grants differ from a charitable contribution since both parties benefit.
- (e) Statements, Part 9, Question 16 Collect and Retain personally identifiable information of customers. The Debtors collect a limited amount of information about customers. Examples of the types of information collected by the Debtors include, among other things, name, mailing address, telephone number, email and addresses.
 - Please see the Debtor's privacy policy at https://www.eigerbio.com/privacy-policy/.
- (f) Statements, Part 9, Question 17– ERISA Plan as an Employee Benefit. The Debtors sponsor a 401(k) plan for their employees.
- (g) Statements, Part 10, Question 20 Off-premises storage. The Debtors use certain third parties, including, for example, storage of product samples, raw materials, and finished goods. The Debtors perform inventory counts at Eiger to ensure accurate inventory records.
- (h) Statements, Part 13, Question 25 Businesses in Which the Debtors Have an Interest. Eiger BioPharmaceuticals, Inc. has a 100% interest in EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, EBPI Merger Inc., and EigerBio Europe Limited.
- (i) Statements, Part 13, Question 26 Books, records, and financial statements. The Debtors' common stock was publicly traded on the Nasdaq stock exchange. As of April 11, 2024, the Debtor's common stock was suspended from trading. Prior to the suspension of trading on the Nasdaq, the Debtors reported their financial results directly to the U.S. Securities and Exchange Commission (the "SEC") for compliance with regulations. Because the SEC filings and the website are public record, the Debtors do not maintain records of the parties that requested or obtained copies of any of the SEC filings from the SEC or the debtors.
- (j) Statements, Part 13, Question 27 Inventories Supervisor and Dates of Inventories Taken Within 2 years. The Debtors perform inventory counts of raw materials and finished goods inventories on an annual basis or as needed for operational reasons. The information included in response to Question 27 reflects the last five (5) inventory dates.
- (k) Statements, Part 13, Question 28 and 29 Current and Former Officer and Directors. While the Debtors have made reasonable best efforts to list all applicable officers and directors for each Debtor in response to Statement Questions 28 and 29, some may have been omitted. Disclosures relate specifically to terminated job titles or positions and are not indicative of the individuals' current employment status with the Debtors.

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Main Document Page 16 of 63

(1) Statements, Part 13, Question 30 – Payments, Distributions, or Withdrawals to Insiders. Refer to Statement Question 4 for this item.

* * * * *

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Main Document Page 17 of 63

Fill in this information to	o identify the case:	
Debtor name Eiger BioPharma	ceuticals, Inc.	
United States Bankruptcy Court	for the: Northern District of Texas, Dallas Division	
Case number (If known) 24-800	040 (SGJ)	

☐ Check if this is an amended filing

Official Form 207

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

04/22

The debtor must answer every question. If more space is needed, attach a separate sheet to this form. On the top of any additional pages, write the debtor's name and case number (if known).

	Identify the beginning and e year, which may be a calend	ending date dar year	s of the deb	tor's	fiscal		urces of revenue eck all that apply		revenue deductions and ons)
	From the beginning of the fiscal year to filing date:		1/01/2024 MM/DD/YYYY	to	04/01/2024		Operating a business Other	\$	\$11,976,431.14
	For prior year:	_	1/01/2023 MM/DD/YYYY	to	12/31/2023 MM/DD/YYYY		Operating a business Other	\$	\$16,071,822.76
		From 0	1/01/2022	to	12/31/2022	$\overline{\checkmark}$	Operating a business		
nclu	For the year before that: n-business revenue ude revenue regardless of whet a lawsuits, and royalties. List ea	her that rev	MM/DD/YYYY				Otheray include interest, dividends	, money colle ed in line 1.	
nclu	n-business revenue ude revenue regardless of whet n lawsuits, and royalties. List ea	her that rev	MM/DD/YYYY		on-business inco	me m aratel	Otheray include interest, dividends	, money colled in line 1. Gross each se	revenue from ource deductions and
nclu	n-business revenue ude revenue regardless of whet n lawsuits, and royalties. List ea	her that revich source a	MM/DD/YYYY	rever	on-business inco	Des	Otheray include interest, dividends y. Do not include revenue list	, money colled in line 1. Gross each so (before	revenue from ource deductions and
nclu	n-business revenue ude revenue regardless of whet lawsuits, and royalties. List ea None From the beginning of the fiscal year to	her that revich source a From $\frac{0}{100}$	renue is taxable and the gross	to	on-business inco nue for each sep	Des revo	Otheray include interest, dividends y. Do not include revenue list scription of sources of enue	, money colleted in line 1. Gross each seach se	revenue from burce deductions and ons)

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Main Document Page 18 of 63case number (If known) 24-80040 (SGJ)

Eiger BioPharmaceuticals, Inc.

Debtor

List Certain	Transfore	Mada	Refore Filing	for	Rankruntcy

an regular employee compensation, within 90 at creditor is less than \$7, 575. (This amount may be adjust the of adjustment.) Reasons for payment or transfer
Check all that apply Secured debt Unsecured loan repayments Suppliers or vendors Services Other Unsecured loan repayments Unsecured debt Unsecured loan repayments Suppliers or vendors Services Other Services Other see that benefited any insider fore filing this case on debts owed to an insider or ferred to or for the benefit of the insider is less than in respect to cases filed on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
Check all that apply Secured debt Unsecured loan repayments Suppliers or vendors Services Other Unsecured loan repayments Suppliers or vendors Secured debt Unsecured loan repayments Suppliers or vendors Services Other Other see that benefited any insider effore filling this case on debts owed to an insider or ferred to or for the benefit of the insider is less than in respect to cases filled on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
Unsecured loan repayments Suppliers or vendors Services Other Secured debt Unsecured loan repayments Suppliers or vendors Suppliers or vendors Services Other Other see that benefited any insider fore filling this case on debts owed to an insider or referred to or for the benefit of the insider is less than a respect to cases filled on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
□ Suppliers or vendors □ Services □ Other □ Secured debt □ Unsecured loan repayments □ Suppliers or vendors □ Services □ Other □ Services □ Other □ Services □ Other □ Other □ See that benefited any insider of ore filling this case on debts owed to an insider or derred to or for the benefit of the insider is less than on respect to cases filed on or after the date of adjustment.) In only one in control of a corporate debtor and their relatives;
☐ Services ☐ Other ☐ Secured debt ☐ Unsecured loan repayments ☐ Suppliers or vendors ☐ Services ☐ Other ☐ Other ☐ Services ☐ Other ☐ In the second debts owed to an insider or referred to or for the benefit of the insider is less than an respect to cases filed on or after the date of adjustment.) In the second debt of a dipustment on respect to cases filed on or after the date of adjustment.) In yone in control of a corporate debtor and their relatives;
☐ Other ☐ Secured debt ☐ Unsecured loan repayments ☐ Suppliers or vendors ☐ Services ☐ Other ☐ Other ☐ Set that benefited any insider or for filling this case on debts owed to an insider or ferred to or for the benefit of the insider is less than in respect to cases filed on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
Secured debt Unsecured loan repayments Suppliers or vendors Services Other see that benefited any insider effore filling this case on debts owed to an insider or ierred to or for the benefit of the insider is less than in respect to cases filed on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
Unsecured loan repayments Suppliers or vendors Services Other see that benefited any insider effore filling this case on debts owed to an insider or ferred to or for the benefit of the insider is less than a respect to cases filed on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
Suppliers or vendors Services Other Set that benefited any insider sfore filing this case on debts owed to an insider or ferred to or for the benefit of the insider is less than in respect to cases filed on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
Services Other See that benefited any insider efore filing this case on debts owed to an insider or ferred to or for the benefit of the insider is less than a respect to cases filed on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
Services Other See that benefited any insider efore filing this case on debts owed to an insider or ferred to or for the benefit of the insider is less than a respect to cases filed on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
se that benefited any insider efore filing this case on debts owed to an insider or ferred to or for the benefit of the insider is less than a respect to cases filed on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
se that benefited any insider efore filing this case on debts owed to an insider or ferred to or for the benefit of the insider is less than a respect to cases filed on or after the date of adjustment.) nyone in control of a corporate debtor and their relatives;
or value Reasons for payment or transfer
Reasons for payment or transfer

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Main Document Page 19 of 63 Case number (If known) 24-80040 (SGJ)

Eiger BioPharmaceuticals, Inc. Debtor

	at a foreclosure sale, transferred by				
V	None				
	Creditor's name and address	Description	n of the property	Date	Value of proper
5.1					\$
	Street				
	City State Zip	Code			
.2					\$
	Street				
	prieet				
	City State Zip	Code			
Z	debtor without permission or refused None Creditor's name and address		n of the action creditor to		
				taken	
_					 \$
-	reet				\$
-					\$
-	reet ty State Zip C	Code			\$
-		Code	of account number: XXXX		\$
7	ty State Zip O	Code Last 4 digits			\$
- t	ty State Zip C	Last 4 digits	of account number: XXXX		\$
e ist	Legal Actions or Assignal actions, administrative proceedings, investi	Last 4 digits nments ings, court actions, e	of account number: XXXX xecutions, attachments, and audits by form	 or governmental audits	
t t	ty State Zip C Legal Actions or Assignal actions, administrative proceed	Last 4 digits nments ings, court actions, e	of account number: XXXX xecutions, attachments, and audits by form	 or governmental audits	
isi	Legal Actions or Assignal actions, administrative proceeding the legal actions, proceedings, invest involved in any capacity-within 1 year None See Attached Rider	Last 4 digits nments ings, court actions, e igations, arbitrations, r r before filing this case	of account number: XXXX xecutions, attachments, nediations, and audits by form	 or governmental audits ederal or state agencies ir	n which the debtor
t :	Legal Actions or Assignated actions, administrative proceeding the legal actions, proceedings, invest involved in any capacity-within 1 year None See Attached Rider Case title	Last 4 digits nments ings, court actions, e igations, arbitrations, r r before filing this case	of account number: XXXX xecutions, attachments, nediations, and audits by formations.	or governmental audits ederal or state agencies in ency's name and address	n which the debtor Status of case
t e	Legal Actions or Assignal actions, administrative proceeding the legal actions, proceedings, invest involved in any capacity-within 1 year None See Attached Rider	Last 4 digits nments ings, court actions, e igations, arbitrations, r r before filing this case	of account number: XXXX xecutions, attachments, and audits by form Court or age	 or governmental audits ederal or state agencies ir	n which the debtor Status of case
t :	Legal Actions or Assignated actions, administrative proceeding the legal actions, proceedings, invest involved in any capacity-within 1 year None See Attached Rider Case title	Last 4 digits nments ings, court actions, e igations, arbitrations, r r before filing this case	of account number: XXXX xecutions, attachments, nediations, and audits by formations.	or governmental audits ederal or state agencies in ency's name and address	ss Status of case Pending On appeal
t :	Legal Actions or Assignal actions, administrative proceeding the legal actions, proceedings, invest involved in any capacity-within 1 year None See Attached Rider Case title	Last 4 digits nments ings, court actions, e igations, arbitrations, r r before filing this case	of account number: XXXX xecutions, attachments, and audits by form Court or ag	or governmental audits ederal or state agencies in ency's name and address	ss Status of case Pending On appeal
.e ist /a:	Legal Actions or Assignal actions, administrative proceeding the legal actions, proceedings, invest involved in any capacity-within 1 year None See Attached Rider Case title	Last 4 digits nments ings, court actions, e igations, arbitrations, r r before filing this case	of account number: XXXX Executions, attachments, and audits by form Court or age Street City	or governmental audits ederal or state agencies in ency's name and address	Status of case Pending On appeal Concluded
t:	Legal Actions or Assignated actions, administrative proceeding the legal actions, proceedings, invest involved in any capacity-within 1 year None See Attached Rider Case title Case number	Last 4 digits nments ings, court actions, e igations, arbitrations, r r before filing this case Nature of case	of account number: XXXX Executions, attachments, and audits by form Court or age Street City Court or age	or governmental audits ederal or state agencies in ency's name and address	Status of case Pending On appeal Concluded Status of case
eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee	Legal Actions or Assignated actions, administrative proceeding the legal actions, proceedings, invest involved in any capacity-within 1 year None See Attached Rider Case title Case number	Last 4 digits nments ings, court actions, e igations, arbitrations, r r before filing this case Nature of case	of account number: XXXX Executions, attachments, and audits by form Court or age Street City Court or age	or governmental audits ederal or state agencies in ency's name and address	Status of case Pending On appeal Concluded Status of case

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc ioPharmaceuticals, Inc. Main Document Page 20 of 63 Case number (If known) 24-80040 (SGJ)

	Ousc 27 00
ebtor	Eiger BioPharmaceuticals, Ir

1	None			
	Custodian's name and address	Description of the property	Value	
			\$	
	Street	Case title	Court name and ac	Idress
	City State Zip Code	Case number		
		Date of order or assignment		
Li	4: Certain Gifts and Charitable Contributions the debtulue of the gifts to that recipient is less than \$1	or gave to a recipient within 2 years before filing t	his case unless the a	nggregate
]	None Recipient's name and address	Description of the gifts or contributions	Dates given	Value
	GORDON RESEARCH CONFERENCES 512 LIBERTY LANE WEST KINGSTON, RI 02892	Cash Donation	2/16/2024	\$\$1,500
	Recipient's relationship to debtor Nonprofit Organization			
.2	·			\$\$
.2	·			_ \$
.2	·			\$\$
	Nonprofit Organization			\$\$
rt ,	Nonprofit Organization Recipient's relationship to debtor 5: Certain Losses Ill losses from fire, theft, or other casualty with	nin 1 year before filing this case.		\$\$
rt ,	Nonprofit Organization Recipient's relationship to debtor 5: Certain Losses	Amount of payments received for the loss If you have received payments to cover the loss, for example, from insurance, government compensation, or tort liability, list the total received. List unpaid claims on Official Form 106A/B (Schedule A/B: Assets - Real and Personal Property).	Date of loss	Value of property

Name

Main Document Page 21 of 63 Case number (If known) 24-80040 (SGJ) Debtor Eiger BioPharmaceuticals, Inc.

	6: Certain Payments or Transfers			
	ayments related to bankruptcy			
tŀ	ist any payments of money or other transfers of prone filing of this case to another person or entity, included bankruptcy relief, or filing a bankruptcy case	operty made by the debtor or person acting on behalf luding attorneys, that the debtor consulted about debter.	of the debtor within 1 y consolidation or restru	ear before icturing,
	None See Attached Rider			
	Who was paid or who received the transfer?	If not money, describe any property transferred	Dates	Total amount or value
11.1				\$
	Address			
	Street			
	City State Zip Code			
	Email or website address			
	Who made the payment, if not debtor?			
	Who was paid or who received the transfer?	If not money, describe any property transferred	Dates	Total amount or value
11.2	2			\$
	Address			
	Street			
	City State Zip Code			
	Email or website address			
	Who made the payment, if not debtor?			
		-		
. 8	Self-settled trusts of which the debtor is a benef	iciary		
L th	ist any payments or transfers of property made by this case to a self-settled trust or similar device.	the debtor or a person acting on behalf of the debtor v	vithin 10 years before t	he filing of
D	o not include transfers already listed on this statem	nent.		
7	None			
	Name of trust or device	Describe any property transferred	Dates transfers were made	Total amount or value
				\$

Debtor Eiger BioPharmaceuticals, Inc.

Name

Main Document Page 22 of 63 Case number (If known) 24-80040 (SGJ)

Li ye	Transfers not already listed on this statement ist any transfers of money or other property-by sale ears before the filing of this case to another persor utright transfers and transfers made as security. D	n, other than property transferred in the ordinary co	ourse of business or financ	f of the debtor within 2 ial affairs. Include both
	None Who received transfer?	Description of property transferred or	Date transfer	Total amount or
		payments received or debts paid in exchange	e was made	value
13.1				\$
	Address			
	Street			
	City. Chat. 7in Code			
	City State Zip Code			
	Relationship to debtor			
	Who we arise discount for O	Baradatian of managers to the same	Data tour of an	Total amazont an
	Who received transfer?	Description of property transferred or payments received or debts paid in exchang	Date transfer was made	Total amount or value
13.2	2	paymone received or decree paid in exercising		\$
	• • • • • • • • • • • • • • • • • • • •	·		
	Address			
	Street			
	City State Zip Code			
	City Citate Lip code			
	Relationship to debtor			
	Relationship to debtor			
Part	7: Previous Locations			
	Previous addresses			
	ist all previous addresses used by the debtor within	n 3 years before filing this case and the dates the	addresses were used	
		The years before thing the ease and the dates the	addicases were asea.	
$\overline{\mathbf{V}}$	Does not apply			
	Address		Dates of Occupancy	
14.1			From	То
	Street			
	City State	Zip Code		
14.2	2 Street		From	То
	- Sureer			
	City State	Zip Code		

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Main Document Page 23 of 63 Case number (If known) 24-80040 (SGJ)

Debtor Eiger BioPharmaceuticals, Inc.

Part 8:	Health	Care	Rankriii	ntcies

Is the debtor primarily engaged in offering services and facilities for - diagnosing or transing nitry, deformly, or disease or - providing any surgical, psychiatric, drug treatment, or obstatric care? No. Go to Part 19.	15. H	lealth Ca	are bankruptcies					
Yes, Fill in the information below. Facility name and address Nature of the business operation, including type of survices the debtor provides If debtor provides meals and housing, number of patients in debtor's care	-	diagnosi	ing or treating injury,	deformity, or disea	ase, or			
Facility name and address Nature of the business operation, including type of services mate and housing, number of patients in debtor's care	_							
Services the debtor provides and housing, number of patients in debtor's care								
Cocation where patient records are maintained (if different from facility address). If electronic, identify any service provider. Check all that apply: Electronically Paper		Facility	y name and address	•			ncluding type of	and housing, number of
Location where patient records are maintained (if different from facility address). If electronic, identify any service provider. Check all that apply: Electronically Paper	15.1							
Facility name and address Nature of the business operation, including type of services the debtor provides Gelectronically Paper		Street						
Facility name and address Nature of the business operation, including type of services the debtor provides and housing, number of patients in debtor's care 15.2		City	State	Zip Code	(if different from facility			How are records kept?
Facility name and address Nature of the business operation, including type of services the debtor provides If debtor provides and housing, number of patients in debtor's care patient records are maintained (if different from facility address). If electronic, identify any service provider. Check all that apply: Electronically Paper								Check all that apply:
Facility name and address Nature of the business operation, including type of services the debtor provides If								☐ Electronically
Services the debtor provides and housing, number of patients in debtor's care								☐ Paper
City State Zip Code Location where patient records are maintained (if different from facility address). If electronic, identify any service provider. Check all that apply: Electronically Paper		Facility	y name and address	1			ncluding type of	and housing, number of
Location where patient records are maintained (if different from facility address). If electronic, identify any service provider. Check all that apply: Electronically Paper Part 9: Personally Identifiable Information No. Please see the Debtor's privacy policy at https://www.eigerbio.com/privacy-policy/. No. No No Yes No. No Yes No. Go to Part 10. Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Fill in below Name of plan Employer identification number of the plan See Attached Rider Has the plan been terminated? No No No No No No No No	15.2							
(if different from facility address). If electronic, identify any service provider. Check all that apply: Electronically Paper		Street						
(if different from facility address). If electronic, identify any service provider. Check all that apply: Electronically Paper								
Part 9: Personally Identifiable Information 16. Does the debtor collect and retain personally identifiable information of customers? No. Yes. State the nature of the information collected and retained. No. Yes. State debtor have a privacy policy about that information? No. Yes Yes 17. Within 6 years before filing this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit? No. Go to Part 10. Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Fill in below Name of plan See Attached Rider Has the plan been terminated? No		City	State	Zip Code	(if different from facility			How are records kept?
Part 9: Personally Identifiable Information 16. Does the debtor collect and retain personally identifiable information of customers? No. Yes. State the nature of the information collected and retained. Does the debtor have a privacy policy about that information? No Yes Yes 17. Within 6 years before filling this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit? No. Go to Part 10. Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Beneficial in below Name of plan See Attached Rider Has the plan been terminated? No								Check all that apply:
16. Does the debtor collect and retain personally identifiable information of customers? No. Yes. State the nature of the information collected and retained. Does the debtor have a privacy policy about that information? No Yes 17. Within 6 years before filling this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit? No. Go to Part 10. Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Fill in below Name of plan See Attached Rider Has the plan been terminated? No								☐ Electronically
16. Does the debtor collect and retain personally identifiable information of customers? No. Yes. State the nature of the information collected and retained. Does the debtor have a privacy policy about that information? No Yes No Yes 17. Within 6 years before filling this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit? No. Go to Part 10. Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Fill in below Name of plan See Attached Rider Has the plan been terminated? No								☐ Paper
16. Does the debtor collect and retain personally identifiable information of customers? No. Yes. State the nature of the information collected and retained. Does the debtor have a privacy policy about that information? No Yes No Yes 17. Within 6 years before filling this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit? No. Go to Part 10. Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Fill in below Name of plan See Attached Rider Has the plan been terminated? No	Part	9: Pe	rsonally Identifia	ble Informatio	n			
No. Please see the Debtor's privacy policy at https://www.eigerbio.com/privacy-policy/. Does the debtor have a privacy policy about that information? No. No. Yes 17. Within 6 years before filing this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit? No. Go to Part 10. Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Fill in below Name of plan						n of customer	s?	
Yes. State the nature of the information collected and retained. https://www.eigerbio.com/privacy-policy/. Does the debtor have a privacy policy about that information? No Yes No Yes 17. Within 6 years before filing this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit? No. Go to Part 10. Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Fill in below Name of plan Employer identification number of the plan See Attached Rider EIN: Has the plan been terminated? No				, ,				
No Yes 17. Within 6 years before filing this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit? No. Go to Part 10.	\checkmark	Yes. Sta	ite the nature of the ir	nformation collecte	ed and retained.			
17. Within 6 years before filing this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit? No. Go to Part 10.			No	privacy policy abo	out that information?			
Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Fill in below Name of plan See Attached Rider Has the plan been terminated? No								k), 403(b), or other
Yes. Does the debtor serve as plan administrator? No. Go to Part 10. Yes. Fill in below Name of plan See Attached Rider Has the plan been terminated? No	П	No. Go t	to Part 10.					
Yes. Fill in below Name of plan See Attached Rider Has the plan been terminated? No	_			s plan administrat	or?			
Name of plan See Attached Rider Has the plan been terminated? No			No. Go to Part 10.					
See Attached Rider Has the plan been terminated? □ No			Yes. Fill in below					
Has the plan been terminated?			•				Employer identification	on number of the plan
□ No			See Attached Ride	<u>r</u>			EIN:	
			Has the plan been to	erminated?				
☐ Yes			□ No					
			☐ Yes					

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Main Document Page 24 of 63 Case number (If known) 24-80040 (SGJ)

Debtor Eiger BioPharmaceuticals, Inc.

Name

rtain Financial Accounts. Safe Deposit Boxes, and Storage Units

18. Closed financial accounts	Doposit Boxes, and			
Within 1 year before filing this case, were any fi old, moved, or transferred? Include checking, savings, money market, or ot brokerage houses, cooperatives, associations, a	her financial accounts; c	ertificates of deposit; and sha		
✓ None				
Financial institution name and address	Last 4 digits of account number	Type of account	Date account was closed, sold, moved, or transferred	Last balance before closing or transfer
18.1	XXXX-	☐ Checking		\$
Street City State Zip Code		☐ Savings☐ Money Market☐ Brokerage		
_,		Other		
18.2	XXXX-	☐ Checking ☐ Savings		\$
Street City State Zip Code				
 19. Safe deposit boxes List any safe deposit box or other depository for ✓ None Depository institution name and address 	Names of anyone w		nas or did have within 1 yea	ar before filing this case. Does debtor still have it?
Street				□ No □ Yes
City State Zip Code	Address			
20. Off-premises storage List any property kept in storage units or warehous in which the debtor does business.	ouses within 1 year befor	re filing this case. Do not incl	ude facilities that are in a	part of a building
☐ None See Attached Rider Facility name and address	Names of anyone w	ith access to it Descri	ption of the contents	Does debtor still have it?
				□ No
Street				Yes
City State Zip Code	Address			

Debtor	Eiger BioPharmaceuticals, Inc.	Main Document	Page 25 of 63 Case number (If known)	24-80040 (SGJ)
	Name			

	Property held for another			
	• •	ntrols that another entity owns. Include any pr	operty borrowed from, being stored fo	r, or held in
✓	Owner's name and address	Location of the property	Description of the property	Value
	Cililoi Ciliano ana adarese	200ation of the property	Doddingson of the property	\$
				<u> </u>
	Street			
	City State Zip Code	_		
t	12: Details About Environmental I	nformation		
t	the purpose of Part 12, the following definition			
		vernmental regulation that concerns pollution,	contamination, or hazardous material	,
	regardless of the medium affected (air, land	,		
	S <i>ite</i> means any location, facility, or property formerly owned, operated, or utilized.	r, including disposal sites, that the debtor now	owns, operates, or utilizes or that the	debtor
	Hazardous material means anything that an or a similarly harmful substance.	environmental law defines as hazardous or to	oxic, or describes as a pollutant, conta	minant,
pq	ort all notices. releases. and proceeding	s known, regardless of when they occurred	I.	
	· · · · · · ·	•		
١	Has the debtor been a party in any judici	al or administrative proceeding under any	environmental law? Include settleme	ents and orders.
7	No			
	Yes. Provide details below.			
	Case title	Court or agency name and address	Nature of the case	Status of cas
				Pending
	Case Number	Street		☐ On appeal ☐ Concluded
	Case Number			On appeal Concluded
	Case Number	Street City State Zip Code		
	Case Number			
			ble or potentially liable under or in v	☐ Concluded
(Has any governmental unit otherwise no environmental law?	City State Zip Code	ble or potentially liable under or in v	☐ Concluded
_ 	Has any governmental unit otherwise no environmental law?	City State Zip Code	ble or potentially liable under or in v	☐ Concluded
_ 	Has any governmental unit otherwise no environmental law?	City State Zip Code		☐ Concluded
_ 	Has any governmental unit otherwise no environmental law? No Yes. Provide details below.	City State Zip Code		☐ Concluded
_ 	Has any governmental unit otherwise no environmental law? No Yes. Provide details below. Site name and address	City State Zip Code		☐ Concluded
<u></u>	Has any governmental unit otherwise no environmental law? No Yes. Provide details below.	City State Zip Code		□ Concluded
	Has any governmental unit otherwise no environmental law? No Yes. Provide details below. Site name and address	City State Zip Code tified the debtor that the debtor may be lia Governmental unit name and address		☐ Concluded
_ 	Has any governmental unit otherwise no environmental law? No Yes. Provide details below. Site name and address	City State Zip Code tified the debtor that the debtor may be lia Governmental unit name and address Street		□ Concluded
<u></u>	Has any governmental unit otherwise no environmental law? No Yes. Provide details below. Site name and address	City State Zip Code tified the debtor that the debtor may be lia Governmental unit name and address Street		☐ Concluded
<u></u>	Has any governmental unit otherwise no environmental law? No Yes. Provide details below. Site name and address	City State Zip Code tified the debtor that the debtor may be lia Governmental unit name and address Street		☐ Concluded
_ 	Has any governmental unit otherwise no environmental law? No Yes. Provide details below. Site name and address	City State Zip Code tified the debtor that the debtor may be lia Governmental unit name and address Street		☐ Concluded

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Main Document Page 26 of 63 Case number (If known) 24-80040 (SGJ)

Debtor Eiger BioPharmaceuticals, Inc.

Governmental unit name and address	Environmental law, if known	Date of notice
		_
		=
City State Zip Code		
ness or Connections to Any Business		
or has had an interest n owner, partner, member, or otherwise a perso	on in control within 6 years before filinç	g this case.
in the Schedules.	·	,
Describe the nature of the business	Employer Identification nu Do not include Social Securi	mber ty number or ITIN
	EIN:	
	Dates business existed	
	From To	О
Describe the nature of the business		
	EIN:	
	Dates business existed	
	From To	0
Describe the nature of the business		
	EIN:	
	Dates business existed	
	From To	·o
1	or has had an interest owner, partner, member, or otherwise a person the Schedules. Describe the nature of the business Describe the nature of the business	owner, partner, member, or otherwise a person in control within 6 years before filing in the Schedules. Describe the nature of the business

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Main Document Page 27 of 63 Case number (If known) 24-80040 (SGJ)

Debtor Eiger BioPharmaceuticals, Inc.

	s and bookkeepers who maintained the de	DIDIO S DOOKS AND FECORDS WITHIN 2	z years before filing t	iis case.
☐ None See Atta	ached Rider		Dates of service	
Name and address			Dates of service	
1			From	То
Street				
City	State	Zip Code		
City	State	Zip Gode		
Name and address			Dates of service	
Name and address			Dates of Service	
2			From	То
Street				
City	State	Zip Code		
Oity	Sale	Σiρ σσαc		
☐ None See Atta	years before filing this case. ached Rider			
Name and add	ress		Dates of service	
001.4			_	-
200.1			From	То
26b.1Street			From	To
200.1	State	Zip Code	From	To
Street			From	То
Street	State		From	To
Street City Name and addi	State		Dates of service	
Street	State			To
Street City Name and addi	State		Dates of service	
Street City Name and addit 26b.2	State		Dates of service	
Street City Name and addr 26b.2 Street	State ress	Zip Code	Dates of service	
Street City Name and addit 26b.2 Street City	State ress	Zip Code	Dates of service	То
Street City Name and addi 26b.2 Street City 26c. List all firms or indi	State Fess State	Zip Code	Dates of service	То
Street City Name and addi 26b.2 Street City 26c. List all firms or indi	State State State ividuals who were in possession of the debached Rider	Zip Code	Dates of service From rds when this case is	Tofiled.
Street City Name and addr 26b.2 Street City 26c. List all firms or indi None See Atta Name and addr	State State State ividuals who were in possession of the debached Rider	Zip Code	Dates of service From rds when this case is	Tofiled.
Street City Name and added 26b.2 Street City 26c. List all firms or indi	State State State ividuals who were in possession of the debached Rider	Zip Code	Dates of service From rds when this case is	Tofiled.
Street City Name and addr 26b.2 Street City 26c. List all firms or indi None See Atta Name and addr	State State State ividuals who were in possession of the debached Rider	Zip Code	Dates of service From rds when this case is	Tofiled.

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Main Document Page 28 of 63 Case number (If known) 24-80040 (SGJ)

Debtor Eiger BioPharmaceuticals, Inc.

Street Gray Baula Zap Goods St. List all financial institutions, creditors, and other parties, including mercantile and trade agencies, to whom the debtor issued a financial statement within 2 years before filing this case. None See Attached Rider Name and address 86.1 Street Gray State Zap Goods Name and address Name and address 10 10 10 10 10 10 10 10 10		Name and address			if any books of account and records are unavailable, explain why
Sizes. Sizes Sizes Sizes	26c.2	2			
Sizes. Sizes Sizes Sizes		Street			
Size Attached Rider Name and address Name and address of the debtor's property been taken within 2 years before filing this case? Name of the person who supervised the taking of the inventory Name of the person who supervised the taking of the inventory Name of the person who supervised the taking of the inventory Name and address of the person who has possession of inventory records					
statement within 2 years before filing this case. None See Attached Rider		City	State	Zip Code	
statement within 2 years before filing this case. None See Attached Rider					
Name and address Name of the debtor's property been taken within 2 years before filing this case? No Yes. Give the details about the two most recent inventories. See Attached Rider Name of the person who supervised the taking of the inventory Name and address of the person who has possession of inventory synthems. Name and address of the person who has possession of inventory records	26d.	List all financial institutions, cre statement within 2 years before	ditors, and other parties, including meron filing this case.	cantile and trade agenci	es, to whom the debtor issued a financial
Name and address Name and address		None See Attached Rider			
Name and address Name and address Name of the person who supervised the taking of the inventory Name and address of the person who has possession of inventory records Name and address of the person who has possession of inventory records		Name and address			
Name and address Name and address Name of the person who supervised the taking of the inventory Name and address of the person who has possession of inventory records Name and address of the person who has possession of inventory records					
Name and address Street Name of the person who supervised the taking of the inventory Name and address of the person who has possession of inventory records Name and address of the person who has possession of inventory records	26d.1				_
Name and address Street Dity State Zip Code Noventories ave any inventories of the debtor's property been taken within 2 years before filing this case? No Yes. Give the details about the two most recent inventories. See Attached Rider Name of the person who supervised the taking of the inventory Date of inventory The dollar amount and basis (cost, market, or other basis) of each inventory \$ Name and address of the person who has possession of inventory records		Street			
Street Street City State Zip Code Aventories ave any inventories of the debtor's property been taken within 2 years before filing this case? No Yes. Give the details about the two most recent inventories. See Attached Rider Name of the person who supervised the taking of the inventory Date of inventory market, or other basis) of each inventory \$ Name and address of the person who has possession of inventory records Street		City	State	Zip Code	_
Street Street City State Zip Code Aventories ave any inventories of the debtor's property been taken within 2 years before filing this case? No Yes. Give the details about the two most recent inventories. See Attached Rider Name of the person who supervised the taking of the inventory Date of inventory market, or other basis) of each inventory \$ Name and address of the person who has possession of inventory records Street					
Street Street City State Zip Code Aventories ave any inventories of the debtor's property been taken within 2 years before filing this case? No Yes. Give the details about the two most recent inventories. See Attached Rider Name of the person who supervised the taking of the inventory Date of inventory market, or other basis) of each inventory \$ Name and address of the person who has possession of inventory records Street		Name and address			
Inventories ave any inventories of the debtor's property been taken within 2 years before filling this case? No Yes. Give the details about the two most recent inventories. See Attached Rider Name of the person who supervised the taking of the inventory Date of inventory The dollar amount and basis (cost, market, or other basis) of each inventory \$ Name and address of the person who has possession of inventory records		rumo una address			
nventories ave any inventories of the debtor's property been taken within 2 years before filling this case? No Yes. Give the details about the two most recent inventories. See Attached Rider Name of the person who supervised the taking of the inventory Date of inventory market, or other basis) of each inventory Name and address of the person who has possession of inventory records	26d.2	2			_
Aventories ave any inventories of the debtor's property been taken within 2 years before filing this case? No Yes. Give the details about the two most recent inventories. See Attached Rider Name of the person who supervised the taking of the inventory Date of inventory The dollar amount and basis (cost, market, or other basis) of each inventory Name and address of the person who has possession of inventory records Street		Street			
Name of the person who supervised the taking of the inventory Name and address of the person who has possession of inventory records No See Attached Rider					
Name of the person who supervised the taking of the inventory Name and address of the person who has possession of inventory records No See Attached Rider		City	State	Zip Code	_
Name of the person who supervised the taking of the inventory Name and address of the person who has possession of inventory records No See Attached Rider		City	State	Zip Code	_
Name of the person who supervised the taking of the inventory Name and address of the person who has possession of inventory records Date of inventory Name and address of the person who has possession of inventory records		City	State	Zip Code	_
Yes. Give the details about the two most recent inventories. See Attached Rider Date of inventory Date of inventory Date of inventory Street Date of inventory Street Date of inventory See Attached Rider	nve		State	Zip Code	_
Name of the person who supervised the taking of the inventory Date of inventory Name and address of the person who has possession of inventory records Street		ntories			
Name and address of the person who has possession of inventory records Street	lave	ntories any inventories of the debtor's No	property been taken within 2 years befo	ore filing this case?	
Name and address of the person who has possession of inventory records Street	lave	ntories any inventories of the debtor's No	property been taken within 2 years befo	ore filing this case?	
Name and address of the person who has possession of inventory records Street	lave □ 1 ☑ \	ntories any inventories of the debtor's No Yes. Give the details about the	property been taken within 2 years befo wo most recent inventories. See Attac	ore filing this case? ched Rider Date of	The dollar amount and basis (cost,
inventory records Street	lave □ 1 ☑ \	ntories any inventories of the debtor's No Yes. Give the details about the	property been taken within 2 years befo wo most recent inventories. See Attac	ore filing this case? ched Rider Date of	market, or other basis) of each inventory
Street	lave	ntories e any inventories of the debtor's No Yes. Give the details about the table ame of the person who super	property been taken within 2 years before wo most recent inventories. See Attactives the taking of the inventory	ore filing this case? ched Rider Date of	market, or other basis) of each inventory
Street	Have	ntories any inventories of the debtor's No Yes. Give the details about the same of the person who super	property been taken within 2 years before wo most recent inventories. See Attactives the taking of the inventory	ore filing this case? ched Rider Date of	market, or other basis) of each inventory
	Have	ntories e any inventories of the debtor's No Yes. Give the details about the same of the person who super ame and address of the person wentory records	property been taken within 2 years before we most recent inventories. See Attactivised the taking of the inventory on who has possession of	ched Rider Date of inventory	market, or other basis) of each inventory
	Na Na in	ntories any inventories of the debtor's No Yes. Give the details about the same of the person who super ame and address of the person ventory records	property been taken within 2 years before wo most recent inventories. See Attactivised the taking of the inventory on who has possession of	ore filing this case? ched Rider Date of inventory	market, or other basis) of each inventory
	Na Na Inn	ntories e any inventories of the debtor's No Yes. Give the details about the same of the person who super ame and address of the person ventory records	property been taken within 2 years before wo most recent inventories. See Attactive wised the taking of the inventory on who has possession of	ore filing this case? ched Rider Date of inventory	market, or other basis) of each inventory
	Na Na in	ntories any inventories of the debtor's No Yes. Give the details about the same of the person who super ame and address of the person ventory records	property been taken within 2 years before wo most recent inventories. See Attactivised the taking of the inventory on who has possession of	ore filing this case? ched Rider Date of inventory	market, or other basis) of each inv
	Na Na in	ntories e any inventories of the debtor's No Yes. Give the details about the same of the person who super ame and address of the person ventory records	property been taken within 2 years before wo most recent inventories. See Attactive wised the taking of the inventory on who has possession of	ore filing this case? ched Rider Date of inventory	market, or other basis) of each inventory
	Na Na Street	ntories e any inventories of the debtor's No Yes. Give the details about the same of the person who super ame and address of the person ventory records	property been taken within 2 years before wo most recent inventories. See Attactive wised the taking of the inventory on who has possession of	ore filing this case? ched Rider Date of inventory	market, or other basis) of each inventory

Debtor Case 24-80040-sgj1.

1	Doc 227	Filed 05/	06/24	Entered	05/06/24 23:15	5:34 C)esc
	Main Do	ocument_	Pane	29 of 63	Case number (If known)	24-80040 (8	3GJ)
	Widin De	Joannent	i age	25 01 00			

Name of the person w	who supervised the taking of the inve	entory		The dollar amou narket, or other		easis (cost, of each inventory
				\$		
Name and address of inventory records	the person who has possession of					
Street						
City	State	Zip Code				
28. List the debtor's officers or other people in contro	s, directors, managing members, gel ol of the debtor at the time of the filli	neral partners, men	bers in control,	controlling sha	areholde	rs,
Name	Address		Position interest	and nature of a	ny %	% of interest, if any
See Attached Rider						
	filing of this case, did the debtor ha ne debtor, or shareholders in contro					s,
□ No	io dostor, or ondronordoro in condic	. or the debter who	no longer nota	andoo poontono	•	
✓ Yes. Identify below.						
Name	Address		Position any interes	and nature of est		d during which on or interest eld
See Attached Rider					From	То
	-				From	To
			•		From	To
					From	To
D. Payments, distributions,	or withdrawals credited or given to	insiders				
Within 1 year before filing	this case, did the debtor provide an ins loans, stock redemptions, and options	sider with value in an	y form, including	salary, other cor	npensatio	on, draws,
□ No	rioans, stock redemptions, and options	s exercised :				
☐ Yes. Identify below.						
Name and address of	recipient	Amount of a description property	noney or and value of	Dates		Reason for providing the value
30.1 Refer to SOFA question	<u>n 4</u>					
Street					-	
City	State Zip Code					
Relationship to debto	r					

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Main Document Page 30 of 63 Case number (If known) 24-80040 (SGJ)

Debtor Eiger BioPharmaceuticals, Inc.

	Name and address of recipient	Amount of mone description and property		Dates	Reason for providing the value
30.2					
	Street				
	City State Zip Code				
	Relationship to debtor				
31 V	Vithin 6 years before filing this case, has the debtor been a meml	per of any consolid	lated group	for tax purposes?	
	No		acca group	тог чат рапроссот	
	Yes. Identify below.				
	Name of the parent corporation		Employer lo	dentification numbe	er of the parent
	Eiger BioPharmaceuticals, Inc.		EIN: 33-097	1591	
32. V	Vithin 6 years before filing this case, has the debtor as an employ	yer been responsib	le for contri	buting to a pension	n fund?
\checkmark	Yes. Identify below.				
	Name of the pension fund		Employer lo	dentification number	er of the pension
	TriNet 401(k) Plan	J	EIN: 48-1304	4650	
Part [*]	WARNING Bankruptcy fraud is a serious crime. Making a false sta connection with a bankruptcy case can result in fines up to \$500,000 18 U.S.C. §§ 152, 1341, 1519, and 3571.				property by fraud in
	I have examined the information in this <i>Statement of Financial Affairs</i> is true and correct.	s and any attachmer	nts and have	a reasonable belief	that the information
	I declare under penalty of perjury that the foregoing is true and correct	ot.			
	Executed on 05/06/2024				
	MM / DD / YYYY				
X	/s/ Douglas Staut	Printed name	Douglas Sta	ut	
-	Signature of individual signing on behalf of the debtor	-			
	Position or relationship to debtor Chief Restructuring Officer				
A	are additional pages to Statement of Financial Affairs for Non-Ind	ividuals Filing for I	Bankruptcy	(Official Form 207)	attached?

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 31 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

ABC-PLAN, INC. 440 CESANO COURT STE 309 PALO ALTO, CA 94306	Coupa Pay 1625 Coupa Pay 1708 Coupa Pay 1822 Coupa Pay 1651	01/17/2024 02/14/2024 03/20/2024	Suppliers or Vendors Suppliers or Vendors Suppliers or Vendors		\$9,000.00
	Coupa Pay 1822				1
		03/20/2024	Suppliers or Vendors		\$4,500.00
	Coupa Pay 1651				\$4,500.00
	Couna Pay 1651	1	s	UBTOTAL	\$18,000.00
ACCENTURE LLP 500 W MADISON ST CHICAGO, IL 60661-2592	Ocupa i ay 1001	01/31/2024	Suppliers or Vendors		\$13,298.00
	Coupa Pay 1720	03/05/2024	Suppliers or Vendors		\$17,731.00
			s	UBTOTAL	\$31,029.00
ALLCARE PLUS PHARMACY LLC 50 BEARFOOT ROAD NORTHBOROUGH, MA 01532	NetSuite Check#00000334/3	02/05/2024	Suppliers or Vendors		\$478.28
	NetSuite Check#00000335/5	02/13/2024	Suppliers or Vendors		\$111,300.00
	NetSuite Check#00000335/6	02/13/2024	Suppliers or Vendors		\$111,300.00
	NetSuite Check#00000336/5	03/19/2024	Suppliers or Vendors		\$823.81
			S	UBTOTAL	\$223,902.09
ALTASCIENCES COMPANY CANADA INC. ALTASCIENCES COMPANY INC. 575 ARMAND-FRAPPIER BLVD LAVAL, QC H7V 4B3 CANADA	Coupa Pay 1731	03/05/2024	Suppliers or Vendors		\$4,937.00
OTHVIEN.	Coupa Pay 1852	03/20/2024	Suppliers or Vendors		\$16,524.00
			S	UBTOTAL	\$21,461.00
AXIS CLINICALS LLC 1711 CENTER AVE WEST DILWORTH, MN 56529	Coupa Pay 1615	01/17/2024	Suppliers or Vendors		\$198,368.50
	Coupa Pay 1672	01/31/2024	Suppliers or Vendors		\$8,163.49
	Coupa Pay 1699	02/14/2024	Suppliers or Vendors		\$122,465.25
	Coupa Pay 1746	03/05/2024	Suppliers or Vendors		\$198,368.50
	Coupa Pay 1840	03/20/2024	Suppliers or Vendors		\$175,500.00
			s	UBTOTAL	\$702,865.74
BACHEM BACHEM AMERICAS, INC 1271 AVENIDA CHELSEA VISTA, CA 92081	Coupa Pay 1732	03/05/2024	Suppliers or Vendors		\$42,810.00
			s	UBTOTAL	\$42,810.00
BIORASI LLC 18851 NE 29TH AVE SUITE 800 MIAMI, FL 33180	Coupa Pay 1620	01/18/2024	Suppliers or Vendors		\$884,144.59
,	Coupa Pay 1703	02/14/2024	Suppliers or Vendors		\$134,144.59
	Coupa Pay 1842	03/20/2024	Suppliers or Vendors		\$134,144.59
			S	UBTOTAL	\$1,152,433.77

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 32 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Creditor Name & Address	Check or Wire Number	Payment Date	Reason For Payment		Amount Paid
NAME ON FILE ADDRESS ON FILE	Coupa Pay 1590	01/10/2024	Other- COBRA		\$9,000.98
/ N. S. N. L. S. S. N. N. L. S.	Coupa Pay 1654	01/31/2024	Other- COBRA		\$4,500.49
	Coupa Pay 1738	03/05/2024	Other- COBRA		\$4,500.49
	Coupa Pay 1823	03/20/2024	Other- COBRA		\$4,500.49
				SUBTOTAL	\$22,502.45
BROADRIDGE ICS P.O. BOX 416423 BOSTON, MA 02241-6423	Coupa Pay 1649	01/31/2024	Services		\$93.02
	Coupa Pay 1691	02/14/2024	Services		\$25,136.95
				SUBTOTAL	\$25,229.97
CALISYM LLC 781 S. MIDLOTHIAN ROAD #101 MUNDELEIN, IL 60060	Coupa Pay 1688	02/14/2024	Suppliers or Vendors		\$17,125.00
	Coupa Pay 1834	03/20/2024	Suppliers or Vendors		\$21,437.50
				SUBTOTAL	\$38,562.50
CAREMARK, LLC ONE CVS DRIVE WOONSOCKET, RI 02895	NetSuite Check#00000334/4	02/05/2024	Suppliers or Vendors		\$3,500.00
WOONGONET, N. SESSO	NetSuite Check#00000334/5	02/05/2024	Suppliers or Vendors		\$3,500.00
	NetSuite Check#00000336/7	03/19/2024	Suppliers or Vendors		\$3,500.00
				SUBTOTAL	\$10,500.00
CHARLES RIVER LABORATORIES 251 BALLARDVALE STREET WILMINGTON, MA 01887-1096	NetSuite Check#00000333/1	01/29/2024	Suppliers or Vendors		\$3,615.00
	NetSuite Check#00000333/2	01/29/2024	Suppliers or Vendors		\$8,495.00
	NetSuite Check#00000333/3	01/29/2024	Suppliers or Vendors		\$1,920.00
	NetSuite Check#00000333/4	01/29/2024	Suppliers or Vendors		\$1,760.00
				SUBTOTAL	\$15,790.00
CHARLES RIVER LABORATORIES DEN BOSCH BV (F/K/A WIL RESEARCH EUROPE B.V.) HAMBAKENWETERING 7 DD'S-HERTOGENBOSCH NOORD BRABANT, 5231 NETHERLANDS	NetSuite Check#Wire Payment 2024020527638194	02/06/2024	Suppliers or Vendors		\$77,790.00
				SUBTOTAL	\$77,790.00
CLINIGEN INC. IDIS HOUSE CHURCHFIELD ROAD WEYBRIDGE SURREY, KT46 8DB UNITED KINGDOM	Coupa Pay 1614	01/17/2024	Suppliers or Vendors		\$39,551.81
	Coupa Pay 1657	01/31/2024	Suppliers or Vendors		\$10,163.60
	Coupa Pay 1752	03/05/2024	Suppliers or Vendors		\$24,944.75
	Coupa Pay 1844	03/20/2024	Suppliers or Vendors		\$18,925.49
				SUBTOTAL	\$93,585.65

Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Case 24-80040-sgj11 Desc Page 33 of 63

Main Document Debtor Name: Eiger BioPharmaceuticals, Inc. Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Creditor Name & Address	Check or Wire Number	Payment Date	Reason For Payment	Amount Paid
CONNOR GROUP GLOBAL SERVICES LLC DEPT 3748 PO BOX 123748 DALLAS, TX 75312-3748	NetSuite Check#00000331/1	01/16/2024	Services	\$37,117.50
	NetSuite Check#00000335/1	02/13/2024	Services	\$21,171.25
	NetSuite Check#00000337/1	03/19/2024	Services	\$51,950.50
			SUBTO	TAL \$110,239.25
CORDEN PHARMA COLORADO INC. 2075 NORTH 55 STREET BOULDER, CO 80301	Coupa Pay 1730	03/05/2024	Suppliers or Vendors	\$36,200.00
	Coupa Pay 1879	03/20/2024	Suppliers or Vendors	\$50,876.00
			SUBTO	TAL \$87,076.00
CRC CONSULTING LLP 12 BARREL RUN ROAD QUAKERTOWN, PA 18951	NetSuite Check#00000334/2	02/05/2024	Services	\$7,175.00
	NetSuite Check#00000336/4	03/19/2024	Services	\$10,150.00
	NetSuite Check#00000338/7	03/19/2024	Services	\$11,550.00
			SUBTO	TAL \$28,875.00
DELAWARE SECRETARY OF STATE DIVISION OF CORPORATIONS POST OFFICE BOX 5509 BINGHAMTON, NY 13902-5509	NetSuite Check#ACH Debit 1154400387	03/05/2024	Other- Taxes	\$40,050.00
			SUBTO	TAL \$40,050.00
DELOITTE TAX LLP 4022 SELLS DRIVE HERMITAGE, TN 37076	Coupa Pay 1700	02/14/2024	Services	\$28,890.00
			SUBTO	TAL \$28,890.00
DIGITAL MEDIA INNOVATIONS LLC C/O WEST TECHNOLOGY GROUP, LLC PO BOX 74007143 CHICAGO, IL 60674-7143	NetSuite Check#00000332/2	01/15/2024	Services	\$3,624.97
	NetSuite Check#00000335/4	02/13/2024	Services	\$5,664.00
	NetSuite Check#00000336/3	03/19/2024	Services	\$729.00
			SUBTO	TAL \$10,017.97
EQUINITI TRUST COMPANY, LLC. EQUINITI TRUST COMPANY, LLC PO BOX 851699 MINNEAPOLIS, MN 55485-1699	NetSuite Check#Wire Payment 2024011727562190	01/30/2024	Services	\$19,950.00
	Coupa Pay 1648	01/31/2024	Services	\$1,881.00
	NetSuite Check#Wire Payment 2024011727562144	01/31/2024	Services	\$320.61
	Coupa Pay 1726	03/05/2024	Services	\$1,906.00
	Coupa Pay 1838	03/20/2024	Services	\$4,750.82

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Figer RioPharmaceuticals Inc. Main Document Page 34 of 63

Debtor Name: Eiger BioPharmaceuticals, Inc.

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Case Number: 24-80040 (SGJ)

Creditor Name & Address	Check or Wire	Payment Date	Reason For Payment	Amount Paid
	Number			
			SUBTOTA	AL \$28,808.43
EQUITY PLAN SOLUTIONS, LLC 1495 VIRGINIA AVENUE REDWOOD CITY, CA 94061	Coupa Pay 1653	01/31/2024	Services	\$11,090.00
	Coupa Pay 1737	03/05/2024	Services	\$9,731.25
	Coupa Pay 1871	03/20/2024	Services	\$3,837.50
			SUBTOTA	\$24,658.75
EUROPEAN MEDICINES AGENCY DOMENICO SCARLATTILAAN 6 HS AMSTERDAM NORTH HOLLAND, 1083 NETHERLANDS	Coupa Pay 1913	03/20/2024	Services	\$14,532.00
			SUBTOTA	\$14,532.00
EXCELLIS EUROPE LTD. C/O ARMSTRONGS ACCOUNTANTS LTD ALEXANDRA HOUSE, QUEEN STREET LEEK STAFFORDSHIRE, ST13 6LP UNITED KINGDOM	Coupa Pay 1914	03/20/2024	Suppliers or Vendors	\$42,680.00
			SUBTOTA	\$42,680.00
NAME ON FILE ADDRESS ON FILE	Coupa Pay 1628	01/17/2024	Services	\$1,375.00
	Coupa Pay 1749	03/05/2024	Services	\$3,437.50
	Coupa Pay 1904	03/20/2024	Services	\$3,987.50
			SUBTOTA	\$8,800.00
FISHER CLINICAL SERVICES, INC. 13741 COLLECTIONS CENTER DRIVE CHICAGO, IL 60693	Coupa Pay 1612	01/17/2024	Suppliers or Vendors	\$688.00
	Coupa Pay 1663	01/31/2024	Suppliers or Vendors	\$38,514.39
	Coupa Pay 1687	02/14/2024	Suppliers or Vendors	\$11,474.26
	Coupa Pay 1736	03/05/2024	Suppliers or Vendors	\$21,101.45
	Coupa Pay 1833	03/20/2024	Suppliers or Vendors	\$51,386.82
	Coupa Pay 1881	03/20/2024	Suppliers or Vendors	\$22,010.06
			SUBTOTA	\$145,174.98
FRONTAGE LABORATORIES FRONTAGE LABORATORIES, INC. 700 PENNSYLVANIA DRIVE EXTON, PA 19341	Coupa Pay 1696	02/14/2024	Suppliers or Vendors	\$80,190.00
	Coupa Pay 1725	03/05/2024	Suppliers or Vendors	\$7,163.72
			SUBTOTA	AL \$87,353.72
FUJIFILM DIOSYNTH BIOCTECHNOLOGIES USA, INC. FUJIFILM DIOSYNTH BIOTECHNOLOGIES USA, INC. PO BOX 1290 CAROL STREAM, IL 60132-1290	Coupa Pay 1608	01/17/2024	Suppliers or Vendors	\$17,000.00

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 35 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Creditor Name & Address	Check or Wire Number	Payment Date	Reason For Payment		Amount Paid
	Coupa Pay 1740	03/05/2024	Suppliers or Vendors		\$205,500.00
	Coupa Pay 1897	03/20/2024	Suppliers or Vendors		\$120,000.00
				SUBTOTAL	\$342,500.00
GREENBERG TRAURIG, LLP 8400 NW 36TH STREET SUITE 400 DORAL, FL 33166	Coupa Pay 1711	02/20/2024	Services		\$12,993.75
				SUBTOTAL	\$12,993.75
HH CONSULTANCY 16894 ST ANDREWS RD CALEDON, ON L7C 2R9 CANADA	NetSuite Check#Wire Payment 2024011527553147	01/17/2024	Services		\$2,984.00
	NetSuite Check#Wire Payment 2024030427743687	03/05/2024	Services		\$5,330.00
	NetSuite Check#Wire Payment 2024031927800622	03/20/2024	Services		\$3,290.00
				SUBTOTAL	\$11,604.00
INNOVATUS CAPITAL PARTNERS, LLC 777 3RD AVENUE 25TH FLOOR NEW YORK, NY 10017	Coupa Pay 1636	02/01/2024	Secured Debt		\$352,058.65
	Coupa Pay 1712	02/29/2024	Secured Debt		\$329,974.55
	Coupa Pay 1882	03/21/2024	Secured Debt		\$353,361.98
				SUBTOTAL	\$1,035,395.18
INOTIV, INC. 2701 KENT AVENUE WEST LAFAYETTE, IN 47906-1350	Coupa Pay 1629	01/17/2024	Suppliers or Vendors		\$34,946.91
				SUBTOTAL	\$34,946.91
INTEGRICHAIN, INC. 8 PENN CENTER, 3RD FLR., 1628 JFK BLVD PHILADELPHIA, PA 19103	Coupa Pay 1670	01/31/2024	Suppliers or Vendors		\$39,538.40
	Coupa Pay 1828	03/20/2024	Suppliers or Vendors		\$24,727.34
				SUBTOTAL	\$64,265.74
INTRINSIK CORP 6605 HURONTARIO STREET, SUITE 500 MISSISSAUGA, ON L5T 0A3 CANADA	NetSuite Check#Wire Payment 2024011527553145	01/17/2024	Suppliers or Vendors		\$9,460.00
	NetSuite Check#Wire Payment 2024021227665347	02/15/2024	Suppliers or Vendors		\$9,730.00
	NetSuite Check#Wire Payment 2024031927800626	03/20/2024	Suppliers or Vendors		\$12,365.00
				SUBTOTAL	\$31,555.00
INTSEL CHIMOS 1 RUE ROYALE- BATIMENT D SAINT-CLOUD, 92210 FRANCE	Coupa Pay 1683	02/12/2024	Suppliers or Vendors		\$71,615.50

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 36 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Creditor Name & Address	Check or Wire Number	Payment Date	Reason For Payment	Amount Paid
			SUBTOTA	L \$71,615.50
IQVIA BIOTECH LLC PO BOX 601070 CHARLOTTE, NC 28260-1070	Coupa Pay 1601	01/17/2024	Suppliers or Vendors	\$7,857.31
	Coupa Pay 1690	02/14/2024	Suppliers or Vendors	\$57,069.67
	Coupa Pay 1811	03/14/2024	Suppliers or Vendors	\$2,877.34
			SUBTOTA	L \$67,804.32
IQVIA INC. PO BOX 601070 CHARLOTTE, NC 28260-1070	Coupa Pay 1591	01/17/2024	Suppliers or Vendors	\$27,481.86
	Coupa Pay 1701	02/14/2024	Suppliers or Vendors	\$4,147.44
	Coupa Pay 1778	03/14/2024	Suppliers or Vendors	\$43,483.42
	Coupa Pay 1810	03/14/2024	Suppliers or Vendors	\$42,103.61
			SUBTOTA	L \$117,216.33
JUMP START TECHNOLOGY INC 2375 GABRIEL AVENUE MOUNTAIN VIEW, CA 94040	NetSuite Check#00000335/8	02/13/2024	Services	\$7,821.50
	NetSuite Check#00000335/9	02/13/2024	Services	\$494.26
	NetSuite Check#00000336/1	03/19/2024	Services	\$7,810.00
	NetSuite Check#00000336/2	03/19/2024	Services	\$12,462.50
	NetSuite Check#00000338/3	03/19/2024	Services	\$938.75
	NetSuite Check#00000338/4	03/19/2024	Services	\$6,288.75
	NetSuite Check#00000338/5	03/19/2024	Services	\$1,389.81
			SUBTOTA	L \$37,205.57
JUSTIN STINDT CONSULTING BRABANTER STRABE 39 COLOGNE, 50672 GERMANY	Coupa Pay 1679	02/13/2024	Services	\$89,937.73
	Coupa Pay 1719	03/06/2024	Services	\$85,000.00
	Coupa Pay 1832	03/20/2024	Services	\$12,500.00
			SUBTOTA	L \$187,437.73
NAME ON FILE ADDRESS ON FILE	Coupa Pay 1627	01/17/2024	Services	\$5,200.00
	Coupa Pay 1641	01/31/2024	Services	\$3,000.00
	Coupa Pay 1710	02/14/2024	Services	\$3,000.00
	Coupa Pay 1751	03/05/2024	Services	\$3,000.00
	Coupa Pay 1825	03/20/2024	Services	\$3,000.00
	Coupa Pay 1903	03/20/2024	Services	\$1,500.00
			SUBTOTA	L \$18,700.00

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Figer RioPharmaceuticals Inc. Main Document Page 37 of 63

Debtor Name: Eiger BioPharmaceuticals, Inc.

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Case Number: 24-80040 (SGJ)

Creditor Name & Address	Check or Wire Number	Payment Date	Reason For Payment		Amount Paid
KILPATRICK TOWNSEND AND STOCKTON LLP KILPATRICK TOWNSEND & STOCKTON LLP PO BOX 945614 ATLANTA, GA 30394	Coupa Pay 1598	01/17/2024	Services		\$50,585.96
,	Coupa Pay 1723	03/05/2024	Services		\$35,087.57
	Coupa Pay 1875	03/20/2024	Services		\$67,021.72
				SUBTOTAL	\$152,695.25
KPMG LLP DEPT 0922 PO BOX 120922 DALLAS, TX 75312-0922	Coupa Pay 1916	03/26/2024	Services		\$172,900.00
				SUBTOTAL	\$172,900.00
KRYOCAL, LLC DBA KYROSPHERE 14001 WESTON PARKWAY, SUITE 106 CARY, NC 27513	Coupa Pay 1665	01/31/2024	Suppliers or Vendors		\$6,562.50
	Coupa Pay 1748	03/05/2024	Suppliers or Vendors		\$6,562.50
				SUBTOTAL	\$13,125.00
NAME ON FILE ADDRESS ON FILE	NetSuite Check#Wire Payment 2024010427511753	01/05/2024	Services		\$25,000.00
				SUBTOTAL	\$25,000.00
LONZA BEND, INC. P.O. BOX 745820 ATLANTA, GA 30374-5820	NetSuite Check#00000338/2	03/19/2024	Suppliers or Vendors		\$12,100.00
				SUBTOTAL	\$12,100.00
MCDONALD FAMILY COMPANY LLC 2183 PARK BLVD. PALO ALTO, CA 94306	Coupa Pay 1668	01/31/2024	Other- Rent/Utilities		\$48,976.90
THE HEIG, SHOTOUS	Coupa Pay 1780	03/14/2024	Other- Rent/Utilities		\$8,840.70
	Coupa Pay 1894	03/20/2024	Other- Rent/Utilities		\$11,984.65
				SUBTOTAL	\$69,802.25
NAME ON FILE ADDRESS ON FILE	Coupa Pay 1772	03/05/2024	Services		\$25,000.00
-				SUBTOTAL	\$25,000.00
MOSS ADAMS LLP 999 THIRD AVENUE, SUITE 2800 SEATTLE, WA 98104	Coupa Pay 1850	03/20/2024	Services		\$95,666.91
,	Coupa Pay 1902	03/20/2024	Services		\$59,728.71
				SUBTOTAL	\$155,395.62
NASDAQ CORPORATE SOLUTIONS NASDAQ CORPORATE SOLUTIONS, LLC - LBX #11700 P.O. BOX 780700 PHILADELPHIA, PA 19178-0700	Coupa Pay 1836	03/20/2024	Services		\$22,155.25

Filed 05/06/24 Entered 05/06/24 23:15:34 Case 24-80040-sgj11 Doc 227 Desc Page 38 of 63

Main Document Debtor Name: Eiger BioPharmaceuticals, Inc. Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Creditor Name & Address	Check or Wire Number	Payment Date	Reason For Payment		Amount Paid
				SUBTOTAL	\$22,155.25
NASDAQ, INC. P.O. BOX 780700 PHILADELPHIA, PA 19178-0700	Coupa Pay 1837	03/20/2024	Services		\$65,500.00
				SUBTOTAL	\$65,500.00
NEWFRONT INSURANCE SERVICES NEWFRONT INSURANCE SERVICES, LLC - NFT CHECKING PO BOX 7841 SAN FRANCISCO, CA 94120-7841	NetSuite Check#Wire Payment 2024031327779016	03/15/2024	Services		\$3,314,249.00
	Coupa Pay 1877	03/20/2024	Services		\$1,875.92
				SUBTOTAL	\$3,316,124.92
NOVATEK NOVATEK INTERNATIONAL 2537 RUE GUENETTE SAINT-LAURENT, QC H4R2E9 CANADA	Coupa Pay 1766	03/05/2024	Suppliers or Vendors		\$74,880.00
				SUBTOTAL	\$74,880.00
ORACLE AMERICA INC. BANK OF AMERICA LOCKBOX SERVICES ORACLE AMERICA INC. 15612 COLLECTIONS CENTER DRIVE CHICAGO, IL 60693	Coupa Pay 1605	01/17/2024	Services		\$922.46
,	Coupa Pay 1843	03/20/2024	Services		\$28,638.00
				SUBTOTAL	\$29,560.46
PACIFIC PHARMACEUTICAL SERVICES 4850 JOULE ST, #A-8 RENO, NV 89502	Coupa Pay 1597	01/17/2024	Suppliers or Vendors		\$19,077.50
	Coupa Pay 1645	01/31/2024	Suppliers or Vendors		\$19,077.50
	Coupa Pay 1722	03/05/2024	Suppliers or Vendors		\$20,007.50
	Coupa Pay 1873	03/20/2024	Suppliers or Vendors		\$23,282.50
				SUBTOTAL	\$81,445.00
PATHEON INC PO BOX 74007046 CHICAGO, IL 60674-7046	Coupa Pay 1613	01/17/2024	Suppliers or Vendors		\$36,468.65
,	Coupa Pay 1661	01/31/2024	Suppliers or Vendors		\$6,060.97
	Coupa Pay 1698	02/14/2024	Suppliers or Vendors		\$44,636.00
	Coupa Pay 1745	03/05/2024	Suppliers or Vendors		\$28,457.99
	Coupa Pay 1839	03/20/2024	Suppliers or Vendors		\$68,264.98
	Coupa Pay 1885	03/20/2024	Suppliers or Vendors		\$18,907.00
				SUBTOTAL	\$202,795.59
PATHEON MANUFACTURING SERVICES LLC 5900 MARTIN LUTHER KING JR HWY. GREENVILLE, NC 27834	Coupa Pay 1639	01/31/2024	Suppliers or Vendors		\$30,276.08

Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Case 24-80040-sgj11 Desc Page 39 of 63

Main Document Debtor Name: Eiger BioPharmaceuticals, Inc.

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Case Number: 24-80040 (SGJ)

Creditor Name & Address	Check or Wire Number	Payment Date	Reason For Payment	Amount Paid
	Coupa Pay 1707	02/14/2024	Suppliers or Vendors	\$3,216.00
	Coupa Pay 1768	03/05/2024	Suppliers or Vendors	\$15,031.00
	Coupa Pay 1900	03/20/2024	Suppliers or Vendors	\$64,437.00
			SUBTOTAL	. \$112,960.08
PATHEON UK LIMITED PATHEON LIMITED, ACCOUNTS KINGFISHER DRIVE COVINGHAM, SN3 5BZ UNITED KINGDOM	Coupa Pay 1593	01/17/2024	Suppliers or Vendors	\$9,641.18
	Coupa Pay 1911	03/20/2024	Suppliers or Vendors	\$10,188.10
			SUBTOTAL	\$19,829.28
PHARMADIRECTIONS ATTN: ACCOUNT RECEIVABLE 15100 WESTON PARKWAY SUITE 101 CARY, NC 27513	Coupa Pay 1611	01/17/2024	Suppliers or Vendors	\$6,817.50
,	Coupa Pay 1728	03/05/2024	Suppliers or Vendors	\$3,172.50
	Coupa Pay 1878	03/20/2024	Suppliers or Vendors	\$1,957.50
			SUBTOTAL	\$11,947.50
REAL STAFFING GROUP SPECIALIST STAFFING SOLUTIONS, INC. 909 FANNIN STREET SUITE P 350 HOUSTON, TX 77010	Coupa Pay 1621	01/17/2024	Services	\$46,215.00
	Coupa Pay 1642	01/31/2024	Services	\$139,322.30
	Coupa Pay 1706	02/14/2024	Services	\$54,535.00
	Coupa Pay 1769	03/05/2024	Services	\$52,146.25
	Coupa Pay 1847	03/20/2024	Services	\$10,530.00
	Coupa Pay 1899	03/20/2024	Services	\$105,787.50
			SUBTOTAL	. \$408,536.05
REGPATH LLC 169 WILLOW ROAD NULL	Coupa Pay 1674	01/31/2024	Services	\$24,300.00
GUILFORD, CT 06437	Coupa Pay 1709	02/14/2024	Services	\$49,219.12
	Coupa Pay 1826	03/20/2024	Services	\$18,000.00
			SUBTOTAL	. \$91,519.12
RESOURCES CONNECTION LLC (DBA COUNTSY) COUNTSY PO BOX 740909 LOS ANGELES, CA 90074-0909	Coupa Pay 1616	01/17/2024	Services	\$2,969.15
	Coupa Pay 1660	01/31/2024	Services	\$2,545.10
	Coupa Pay 1697	02/14/2024	Services	\$3,066.70
	Coupa Pay 1756	03/05/2024	Services	\$3,246.80
	Coupa Pay 1846	03/20/2024	Services	\$2,912.30

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 40 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Creditor Name & Address	Check or Wire Number	Payment Date	Reason For Payment	Amount Paid
	Coupa Pay 1888	03/20/2024	Services	\$6,620.75
			SUBTO	TAL \$21,360.80
ROPES & GRAY LLP 800 BOYLSTON STREET, PRUDENTIAL TOWER BOSTON, MA 02199	Coupa Pay 1759	03/05/2024	Services	\$49,525.00
	Coupa Pay 1779	03/14/2024	Services	\$38,535.00
	Coupa Pay 1892	03/20/2024	Services	\$36,592.50
			SUBTO	OTAL \$124,652.50
RRD INTERNATIONAL, LLC 7361 CALHOUN PLACE, SUITE 510 ROCKVILLE, MD 20855	Coupa Pay 1686	02/20/2024	Suppliers or Vendors	\$499,154.25
TROOKVILLE, IND 20000	Coupa Pay 1735	03/05/2024	Suppliers or Vendors	\$195,685.50
	Coupa Pay 1920	03/26/2024	Suppliers or Vendors	\$202,449.25
			SUBTO	DTAL \$897,289.00
RTI INTERNATIONAL RESEARCH TRIANGLE INSTITUTE 3040 E. CORNWALLIS ROAD RESEARCH TRIANGLE PARK, NC 27709	Coupa Pay 1637	01/31/2024	Suppliers or Vendors	\$143,126.00
			SUBTO	TAL \$143,126.00
RXCROSSROADS 3 PL LLC RXCROSSROADS 3PL LLC 1001 CHERI WAY SUITE 100 FAIRDALE, KY 40118	Coupa Pay 1673	01/31/2024	Services	\$9,333.18
,	Coupa Pay 1704	02/14/2024	Services	\$9,386.18
	Coupa Pay 1898	03/20/2024	Services	\$18,623.65
			SUBTO	OTAL \$37,343.01
SCIENSUS INTERNATIONAL (NETHERLANDS) BV 107 STATION STREET BURTON-UPON-TRENT, DE14 1SZ UNITED KINGDOM	Coupa Pay 1631	01/31/2024	Suppliers or Vendors	\$12,420.00
	Coupa Pay 1680	02/13/2024	Suppliers or Vendors	\$118,647.12
	Coupa Pay 1718	03/06/2024	Suppliers or Vendors	\$12,420.00
	Coupa Pay 1831	03/20/2024	Suppliers or Vendors	\$816.00
	Coupa Pay 1915	03/21/2024	Suppliers or Vendors	\$63,794.60
			SUBTO	TAL \$208,097.72
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA C/O PENN CENTER FOR INNOVATION PO BOX 785546 PHILADELPHIA, PA 19178-5546	Coupa Pay 1607	01/17/2024	Services	\$8,706.04
	Coupa Pay 1841	03/20/2024	Services	\$1,984.00

Filed 05/06/24 Entered 05/06/24 23:15:34 Case 24-80040-sgj11 Doc 227 Desc Page 41 of 63

Main Document Debtor Name: Eiger BioPharmaceuticals, Inc. Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Creditor Name & Address	Check or Wire Number	Payment Date	Reason For Payment		Amount Paid
				SUBTOTAL	\$10,690.04
WATERHOUSE BRANDS LLC 205 BIRCH AVENUE LARKSPUR, CA 94939	Coupa Pay 1634	01/31/2024	Suppliers or Vendors		\$23,325.50
				SUBTOTAL	\$23,325.50
WHEELHOUSE LIFE SCIENCE ADVISORS 927 REGALO WAY SAN RAMON, CA 94583	Coupa Pay 1624	01/17/2024	Suppliers or Vendors		\$18,000.00
	Coupa Pay 1635	01/31/2024	Suppliers or Vendors		\$18,750.00
	Coupa Pay 1760	03/05/2024	Suppliers or Vendors		\$15,562.50
	Coupa Pay 1883	03/20/2024	Suppliers or Vendors		\$42,750.00
				SUBTOTAL	\$95,062.50
WORLD COURIER INC. P.O. BOX 842325 BOSTON, MA 02284-2325	Coupa Pay 1596	01/17/2024	Suppliers or Vendors		\$8,662.66
				SUBTOTAL	\$8,662.66
ZENQMS 40 COULTER AVE # 265 ARDMORE, PA 19003	Coupa Pay 1702	02/14/2024	Suppliers or Vendors		\$39,590.78
				SUBTOTAL	\$39,590.78

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Main Document Page 42 of 63

Debtor Name: Eiger BioPharmaceuticals, Inc.

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Debtor	Ending Balance Description	Related Entity	Balance - March 31, 2023 Receivable (Payable)	Balance - March 31, 2024 Receivable (Payable)	Net Year Activity Increase (Decrease)
Eiger BioPharmaceuticals, Inc.	Intercompany Trade Payable To	EigerBio Europe Limited	\$ (108.84)	\$ (3,882,386.00)	\$ 3,882,277.16

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 43 of 63 Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Insider's Name and Address	Relationship to Debtor	Total Amount or Value	Dates	Reason for Payment or Transfer
ALVAREZ & MARSAL NORTH AMERICA LLC 600 MADISON AVENUE 8TH FLOOR NEW YORK, NY 10022	Chief Restructuring Officer	\$100,000.00	02/14/2024	Bankruptcy Professional Fees
ALVAREZ & MARSAL NORTH AMERICA LLC 600 MADISON AVENUE 8TH FLOOR NEW YORK, NY 10022	Chief Restructuring Officer	\$253,445.69	03/19/2024	Bankruptcy Professional Fees
ALVAREZ & MARSAL NORTH AMERICA LLC 600 MADISON AVENUE 8TH FLOOR NEW YORK, NY 10022	Chief Restructuring Officer	\$223,816.14	03/29/2024	Bankruptcy Professional Fees
NAME ON FILE ADDRESS ON FILE	Director	\$16,875.00	06/29/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$16,875.00	09/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$16,875.00	12/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$16,875.00	03/20/2024	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Former Director	\$16,125.00	06/29/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Former Director	\$16,125.00	09/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Former Director	\$13,125.00	12/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Former Director	\$9,375.00	03/20/2024	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$90.71	04/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$90.71	05/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$90.71	06/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$90.78	07/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$649.57	07/18/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$93.29	08/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$386.85	08/29/2023	Employee Expense Reimbursement

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Main Document Page 44 of 63 Case Number: 24-80040 (SGJ)

Debtor Name: Eiger BioPharmaceuticals, Inc.

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Insider's Name and Address	Relationship to Debtor	Total Amount or Value	Dates	Reason for Payment or Transfer
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$93.29	09/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$97.47	10/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$118.85	11/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$93.23	12/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$3,049.96	01/10/2024	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$93.46	01/13/2024	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$300.00	01/21/2024	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$283.78	02/06/2024	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$737.50	02/07/2024	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$238.44	02/08/2024	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$208.87	02/13/2024	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$93.23	03/13/2024	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$41,507.56	04/14/23 - 03/29/24	Benefits
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$334,992.00	04/14/23 - 03/29/24	Bonus
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$2,287.50	04/14/23 - 03/29/24	Other Earnings
NAME ON FILE ADDRESS ON FILE	Chief Technical Officer	\$384,799.92	04/14/23 - 03/29/24	Regular Pay
DANFORTH ADVISORS LLC 91 MIDDLE RD SOUTHBOROUGH, MA 01772	Professional Services Advisory	\$121,625.58	05/30/2023	Services
DANFORTH ADVISORS LLC 91 MIDDLE RD SOUTHBOROUGH, MA 01772	Professional Services Advisory	\$96,318.05	06/30/2023	Services
DANFORTH ADVISORS LLC 91 MIDDLE RD SOUTHBOROUGH, MA 01772	Professional Services Advisory	\$107,124.80	07/18/2023	Services
DANFORTH ADVISORS LLC 91 MIDDLE RD SOUTHBOROUGH, MA 01772	Professional Services Advisory	\$192,588.82	10/11/2023	Services

Main Document Debtor Name: Eiger BioPharmaceuticals, Inc. Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Insider's Name and Address	Relationship to Debtor	Total Amount or Value	Dates	Reason for Payment or Transfer
DANFORTH ADVISORS LLC 91 MIDDLE RD SOUTHBOROUGH, MA 01772	Professional Services Advisory	\$57,893.75	11/14/2023	Services
DANFORTH ADVISORS LLC 91 MIDDLE RD SOUTHBOROUGH, MA 01772	Professional Services Advisory	\$124,712.50	12/27/2023	Services
DANFORTH ADVISORS LLC 91 MIDDLE RD SOUTHBOROUGH, MA 01772	Professional Services Advisory	\$38,062.50	01/17/2024	Services
DANFORTH ADVISORS LLC 91 MIDDLE RD SOUTHBOROUGH, MA 01772	Professional Services Advisory	\$50,981.25	03/05/2024	Services
DANFORTH ADVISORS LLC 91 MIDDLE RD SOUTHBOROUGH, MA 01772	Professional Services Advisory	\$59,906.25	03/20/2024	Services
DANFORTH ADVISORS LLC 91 MIDDLE RD SOUTHBOROUGH, MA 01772	Professional Services Advisory	\$50,000.00	03/29/2024	Services
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$150.00	04/04/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$23.89	04/05/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$1,021.49	04/06/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$258.00	04/07/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$326.52	04/11/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$497.20	04/12/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$221.85	04/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$149.38	04/18/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$10.92	04/19/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$1,108.45	04/20/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$260.00	04/21/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$209.93	04/25/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$179.84	04/26/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$1,172.37	04/27/2023	Employee Expense Reimbursement

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Main Document Page 46 of 63 Case Number: 24-80040 (SGJ)

Debtor Name: Eiger BioPharmaceuticals, Inc.

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Relationship to Debtor	Total Amount or Value	Dates	Reason for Payment or Transfer
Director, Chief Executive Officer	\$258.00	04/28/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$166.24	05/02/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$32.10	05/03/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$1,266.28	05/04/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$247.50	05/05/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$58.50	05/08/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$171.35	05/09/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$36.65	05/10/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$1,513.67	05/11/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$68.63	05/16/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$651.89	05/17/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$130.00	05/18/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$157.60	05/22/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$248.70	05/23/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$1,106.64	05/24/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$195.00	05/25/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$16.14	05/30/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$37.49	05/31/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$778.50	06/01/2023	Employee Expense Reimbursement
Director, Chief Executive Officer	\$56.07	06/26/2023	Employee Expense Reimbursement
	Director, Chief Executive Officer Director, Chief Executive Officer	Director, Chief Executive Officer \$166.24 Director, Chief Executive Officer \$32.10 Director, Chief Executive Officer \$1,266.28 Director, Chief Executive Officer \$247.50 Director, Chief Executive Officer \$58.50 Director, Chief Executive Officer \$171.35 Director, Chief Executive Officer \$36.65 Director, Chief Executive Officer \$36.65 Director, Chief Executive Officer \$1,513.67 Director, Chief Executive Officer \$68.63 Director, Chief Executive Officer \$130.00 Director, Chief Executive Officer \$130.00 Director, Chief Executive S157.60 Director, Chief Executive Officer \$1,106.64 Director, Chief Executive S14.106.64 Director, Chief Executive S157.60 Director, Chief Executive S14.106.64 Director, Chief Executive S157.60 Director, Chief Executive S14.106.64 Director, Chief Executive S157.60 Director, Chief Executive S16.14 Director, Chief Executive S16.14 Director, Chief Executive S1778.50 Director, Chief Executive S1778.50 Director, Chief Executive S778.50 Director, Chief Executive S778.50	Director, Chief Executive \$258.00 04/28/2023

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Main Document Page 47 of 63 Case Number: 24-80040 (SGJ)

Debtor Name: Eiger BioPharmaceuticals, Inc.

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Insider's Name and Address	Relationship to Debtor	Total Amount or Value	Dates	Reason for Payment or Transfer
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$165.29	06/28/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$613.83	06/29/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$171.50	06/30/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$379,728.81	07/03/2023	Incentive Stock Options
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$166,999.32	07/03/2023	Non-Qualified Stock Options
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$271.94	07/18/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$901.66	07/19/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$210.00	07/20/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$239.85	08/10/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$592.38	08/11/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$245.21	08/16/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$168.35	08/29/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$702.30	08/31/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$63.90	09/01/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$56.06	09/26/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$582.32	09/27/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$171.50	09/28/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$220.50	10/31/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$107.88	11/01/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$984.52	11/02/2023	Employee Expense Reimbursement

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Main Document Page 48 of 63 Case Number: 24-80040 (SGJ)

Debtor Name: Eiger BioPharmaceuticals, Inc.

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Insider's Name and Address	Relationship to Debtor	Total Amount or Value	Dates	Reason for Payment or Transfer
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$241.50	11/03/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$154,414.90	04/14/23 - 03/29/24	Benefits
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$1,075,582.44	04/14/23 - 03/29/24	Bonus
NAME ON FILE ADDRESS ON FILE	Director, Chief Executive Officer	\$644,511.30	04/14/23 - 03/29/24	Regular Pay
NAME ON FILE ADDRESS ON FILE	Former Chief Executive Officer	\$26,211.80	03/15/23 - 03/29/24	Benefits
NAME ON FILE ADDRESS ON FILE	Former Chief Executive Officer	\$1,086,800.00	03/15/23 - 03/29/24	Other Earnings
EIGER GROUP INTERNATIONAL, INC. ADDRESS ON FILE	Professional Services Advisory	\$16,750.00	06/29/2023	Board of Director Fees
EIGER GROUP INTERNATIONAL, INC. ADDRESS ON FILE	Professional Services Advisory	\$16,750.00	09/27/2023	Board of Director Fees
EIGER GROUP INTERNATIONAL, INC. ADDRESS ON FILE	Professional Services Advisory	\$16,750.00	12/27/2023	Board of Director Fees
EIGER GROUP INTERNATIONAL, INC. ADDRESS ON FILE	Professional Services Advisory	\$16,750.00	03/20/2024	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Former Chief Commercial Officer	\$251,200.00	03/15/23 - 02/02/24	Bonus
NAME ON FILE ADDRESS ON FILE	Former Chief Commercial Officer	\$13,895.40	03/15/23 - 02/02/24	Other Earnings
NAME ON FILE ADDRESS ON FILE	Former Chief Commercial Officer	\$440,512.74	03/15/23 - 02/02/24	Regular Pay
NAME ON FILE ADDRESS ON FILE	Director	\$17,375.00	06/29/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$17,375.00	09/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$17,375.00	12/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$17,375.00	03/20/2024	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$1,989.02	04/09/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$301.47	04/10/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$346.01	04/11/2023	Employee Expense Reimbursement

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 49 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Insider's Name and Address	Relationship to Debtor	Total Amount or Value	Dates	Reason for Payment or Transfer
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$334.59	04/12/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$421.29	04/13/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$123,600.00	04/28/2023	Non-Qualified Stock Options
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$1,426.11	05/23/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$138.93	05/25/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$866.29	07/12/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$66.60	07/18/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$30.95	07/19/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$51.75	07/20/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$1,706.20	07/21/2023	Employee Expense Reimbursement
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$85,667.80	04/14/23 - 03/29/24	Benefits
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$543,057.00	04/14/23 - 03/29/24	Bonus
NAME ON FILE ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	\$416,145.76	04/14/23 - 03/29/24	Regular Pay
NAME ON FILE ADDRESS ON FILE	Director	\$14,250.00	06/29/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$14,250.00	09/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$14,250.00	12/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$14,250.00	03/20/2024	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$13,125.00	06/29/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$13,125.00	09/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$13,125.00	12/27/2023	Board of Director Fees

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Case Number: 24-80040 (SGJ)

Debtor Name: Eiger BioPharmaceuticals, Inc.

Page 50 of 63 Main Document

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Insider's Name and Address	Relationship to Debtor	Total Amount or Value	Dates	Reason for Payment or Transfer
NAME ON FILE ADDRESS ON FILE	Director	\$13,125.00	03/20/2024	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$42,500.00	06/29/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$42,500.00	09/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$42,500.00	12/27/2023	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Director	\$42,500.00	03/20/2024	Board of Director Fees
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$50,793.75	04/01/2023	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$49,087.50	05/01/2023	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$53,418.75	06/01/2023	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$39,768.75	07/01/2023	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$45,281.25	08/01/2023	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$23,493.75	09/01/2023	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$30,187.50	10/01/2023	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$22,575.00	11/01/2023	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$20,737.50	12/01/2023	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$21,131.25	01/01/2024	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$30,056.25	02/01/2024	Consulting Services
NAME ON FILE ADDRESS ON FILE	Chief Financial Officer	\$28,350.00	03/01/2024	Consulting Services

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Main Document Page 51 of 63

Debtor Name: Eiger BioPharmaceuticals, Inc.

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Debtor	Ending Balance Description	Related Entity	Balance - March 31, 2023	Balance - March 31, 2024	
		* * * * * *	Receivable (Payable)	Receivable (Payable)	Increase (Decrease)
Eiger BioPharmaceuticals, Inc.	Intercompany Trade Payable To	EigerBio Europe Limited	\$ (108.84)	\$ (3,882,386.00)	\$ 3,882,277.16

Filed 05/06/24 Entered 05/06/24 23:15:34 Case 24-80040-sgj11 Doc 227 Desc

Debtor Name: Eiger BioPharmaceuticals, Inc.

Page 52 of 63 Main Document

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 7: Legal actions, administrative proceedings, court actions, executions, attachments, or governmental audits

Case Title	Case Number	Nature of Case	Court Name and Address	Status
SCHOEN V. EIGER BIOPHARMACEUTICALS, INC., ET AL	22-CV-06985	SECURITIES, COMMODITIES, EXCHANGE	UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 450 GOLDEN GATE AVENUE SAN FRANCISCO CA 94102	Concluded

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 53 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 11: Payments related to bankruptcy

Who was paid or who received the transfer?	Email or website	Who made payment, if not the debtor?	If not money, describe any property transferred	Date	Amount
ALVAREZ & MARSAL NORTH AMERICA LLC 600 MADISON AVENUE 8TH FLOOR NEW YORK, NY 10022	https://www.alvarez andmarsal.com/			03/11/2024	\$100,000.00
ALVAREZ & MARSAL NORTH AMERICA LLC 600 MADISON AVENUE 8TH FLOOR NEW YORK, NY 10022	https://www.alvarez andmarsal.com/			03/29/2024	\$223,816.14
ALVAREZ & MARSAL NORTH AMERICA LLC 600 MADISON AVENUE 8TH FLOOR NEW YORK, NY 10022	https://www.alvarez andmarsal.com/			03/20/2024	\$103,445.69
ALVAREZ & MARSAL NORTH AMERICA LLC 600 MADISON AVENUE 8TH FLOOR NEW YORK, NY 10022	https://www.alvarez andmarsal.com/			03/20/2024	\$150,000.00
KURTZMAN CARSON CONSULTANTS LLC 222 N. PACIFIC HIGHWAY 3RD FLOOR EL SEGUNDO, CA 90245	https://www.kccllc.c om/			03/29/2024	\$25,000.00
KURTZMAN CARSON CONSULTANTS LLC 222 N. PACIFIC HIGHWAY 3RD FLOOR EL SEGUNDO, CA 90245	https://www.kccllc.c om/			03/29/2024	\$25,000.00
SIDLEY AUSTIN LLP 555 CALIFORNIA STREET SAN FRANCISCO, CA 94104	https://www.sidley.c om/en/us/			02/12/2024	\$48,270.00
SIDLEY AUSTIN LLP 555 CALIFORNIA STREET SAN FRANCISCO, CA 94104	https://www.sidley.c om/en/us/			03/18/2024	\$196,698.50
SIDLEY AUSTIN LLP 555 CALIFORNIA STREET SAN FRANCISCO, CA 94104	https://www.sidley.c om/en/us/			04/01/2024	\$690,007.61
SSG ADVISORS LLC 300 BARR HARBOR DRIVE SUITE 420 WEST CONSHOHOCKEN, PA 19428	https://www.ssgca.c om/			03/29/2024	\$100,000.00

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 54 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 17: Within 6 years before filing this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit?

Name of Plan	EIN	Terminated?
TriNet 401(k) Plan - Eiger BioPharmaceuticals, Inc. (with Transamerica Retirement Solutions, LLC)	48-1304650	Yes
TriNet 401(k) Plan As Adopted by Eiger BioPharmaceuticals, Inc. (with Empower Retirement, LLC)	48-1304650	No

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 55 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 20: Off-premises storage

Storage Facility Name and Address	Access Names	Address	Contents	Still Have It
ALTASCIENCES 575, BOUL. ARMAND-FRAPPIER LAVAL, QUÉBEC H7V 4B3 CANADA	Various		Human Samples	Yes
AXIS CLINICAL 1711 CENTER AVE W DILWORTH, MN 56529	Various		Human Samples	Yes
BEND RESEARCH 64550 RESEARCH RD BEND, OR 97703	Various		LNF Intermediates	Yes
CORDEN PHARMA 2075 55TH ST BOULDER, CO 80301	Various		LNF Raw Materials & LNF API	Yes
FISHER BIOSERVICES 1001 ALDRIDGE RD VACAVILLE, CA 95688	Various		LMD Raw Materials & LMD API	Yes
FISHER CLINICAL EU MARIE-CURIE-STRASSE 16 RHEINFELDEN, 79618 GERMANY	Various		LMD & LNF Clinical Material	Yes
FISHER CLINICAL US 7554 SCHANTZ RD ALLENTOWN, PA 18106	Various		LMD/LNF/AVX Clinical Material	Yes
FRONTAGE LABORATORIES 700 PENNSYLVANIA DRIVE EXTON, PA 19341	Various		Human Samples	Yes
FUJIFILM 101 J MORRIS COMMONS LANE MORRISVILLE, NC 27560	Various		LMD Hardware	Yes
IQVIA 4820 EMPEROR BOULEVARD DURHAM, NC 27703	Various		Human Samples	Yes
PACIFIC PHARMACEUTICALS 4850 JOULE ST RENO, NV 89502	Various		LMD/LNF/AVX Ref.Materials	Yes
PATHEON - GREENVILLE 5900 M.L.K. JR HWY GREENVILLE, NC 27834	Various		AVX Vials	Yes
PATHEON (CANADA) 2100 SYNTEX CT MISSISSAUGA, ON L5N 3X4 CANADA	Various		LNF Drug Product	Yes
PATHEON (ITALY) VIALE GIAN BATTISTA STUCCHI, 110, 20900 MONZA MB, ITALY	Various		LMD Raw Materials	Yes
Q2 LAB SOLUTIONS 2400 ELLIS ROAD DURHAM, NC 27703	Various		Human Samples	Yes
RX CROSSROADS 6535 STATE HIGHWAY, 161 IRVING, TX 75039	Various		Zokinvy Finished Goods	Yes
SHARP CLINICAL - BETHLEHEM 2400 BAGLYOS CIR BETHLEHEM, PA 18020	Various		LMD Components	Yes
TDL (THE DOCTORS LABORATORY) THE HALO BUILDING, 1 MABLEDON PLACE WC1H 9AX LONDON	Various		Human Samples	Yes

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 56 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 25: Other businesses in which the debtor has or has had an interest

Business Name and Address	Nature of Business Operation	EIN	Existed From	Existed To
EB PHARMA LLC 2155 PARK BOULEVARD PALO ALTO, CA 94306	License Owner of Tipifarnib	61-1748352	10/7/2014	Present
EBPI MERGER INC. 2155 PARK BOULEVARD PALO ALTO, CA 94306	IP Owner	26-3679986	11/6/2008	Present
EIGER BIOPHARMACEUTICALS EUROPE LIMITED 30 UPPER HIGH STREET THAME, OXFORDSHIRE, OX9 3EZ UNITED KINGDOM	Shell Company	8561400 (UK)	6/7/2013	Present
EIGERBIO EUROPE LIMITED ROOM 002, 28-32 PEMBROKE STREET UPPER DUBLIN 2, D02NT28 IRELAND (EIRE)	License Owner of Zokinvy	646778 (Ireland)	3/27/2019	Present

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 57 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 26a: List all accountants and bookkeepers who maintained the debtor's books and records within 2 years before filing this case.

Name and Address	From	То
NAME ON FILE	05/01/2023	Present
ADDRESS ON FILE		
NAME ON FILE	03/01/2023	Present
ADDRESS ON FILE		
NAME ON FILE	05/01/2019	03/01/2023
ADDRESS ON FILE		
NAME ON FILE	04/01/2020	05/01/2023
ADDRESS ON FILE		
NAME ON FILE	12/01/2018	03/01/2023
ADDRESS ON FILE		
NAME ON FILE	03/01/2023	04/29/2024
ADDRESS ON FILE		

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 58 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 26b: List all firms or individuals who have audited, compiled, or reviewed debtor's books of account and records or prepared a financial statement within 2 years before filing this case.

Name and Address	From	То
DELOITTE TAX LLP 4022 SELLS DRIVE HERMITAGE, TN 37076	08/01/2019	Present
KPMG LLP DEPT 0922 PO BOX 120922 DALLAS, TX 75312-0922	10/13/2015	Present
MOSS ADAMS LLP 999 THIRD AVENUE, SUITE 2800 SEATTLE, WA 98104	05/04/2022	Present

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Desc Page 59 of 63 Main Document Case Number: 24-80040 (SGJ)

Debtor Name: Eiger BioPharmaceuticals, Inc.

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 26c: Firms or individuals who were in possession of the debtor's books of account and records when this case is filed.

Name and Address	If unavailable, why?
NAME ON FILE	
ADDRESS ON FILE	
DELOITTE TAX LLP 4022 SELLS DRIVE HERMITAGE, TN 37076	
KPMG LLP DEPT 0922 PO BOX 120922	
DALLAS, TX 75312-0922 NAME ON FILE ADDRESS ON FILE	
NAME ON FILE ADDRESS ON FILE	
MOSS ADAMS LLP 999 THIRD AVENUE, SUITE 2800 SEATTLE, WA 98104	
NAME ON FILE ADDRESS ON FILE	
NAME ON FILE ADDRESS ON FILE	
NAME ON FILE ADDRESS ON FILE	

Case 24-80040-sgj11 Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Doc 227 Filed 05/06/24 Entered 05

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 60 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 26d: List all financial institutions, creditors, and other parties, including mercantile and trade agencies, to whom the debtor issues a financial statement within 2 years before filling this case.

Name and Address

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, EIGER BIOPHARMACEUTICALS, INC. HAS FILED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC") REPORTS ON FORM 8-K, FORM 10-Q, FORM 10-K, ETC. THESE SEC FILINGS CONTAIN CONSOLIDATED FINANCIAL INFORMATION RELATING TO THE DEBTORS. ADDITIONALLY, CONSOLIDATED FINANCIAL INFORMATION FOR THE DEBTORS IS POSTED ON THE COMPANY'S WEBSITE AT

HTTPS://IR.EIGERBIO.COM/FINANCIAL-INFORMATION/SEC-FILINGS. BECAUSE THE SEC FILINGS AND THE WEBSITE ARE PUBLIC RECORD, THE DEBTORS DO NOT MAINTAIN RECORDS OF THE PARTIES THAT REQUESTED OR OBTAINED COPIES OF ANY OF THE SEC FILINGS FROM THE SEC OR THE DEBTORS.

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 61 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 27: Inventories

Supervisor Name	Name and Address of Person in Possession	Date	Amount
NAME ON FILE	NAME ON FILE 4876 STERLING D	03/18/2024	\$515,000
NAME ON FILE	BOULDER, CO 80301 NAME ON FILE 2100 SYNTEX D MISSISSAUGA, ON L5N 7K9 CANADA	03/13/2024	\$700,000
NAME ON FILE	NAME ON FILE 4876 STERLING D BOULDER, CO 80301	12/15/2022	\$1,700,000
NAME ON FILE	NAME ON FILE 63060 NE CORPORATE PL BEND, OR 97701	12/13/2022	\$1,700,000
NAME ON FILE	NAME ON FILE 2100 SYNTEX D MISSISSAUGA, ON L5N 7K9 CANADA	12/12/2022	\$402,000

Case 24-80040-sgj11

Doc 227 Filed 05/06/24 Entered 05/06/24 23:15:34 Main Document

Page 62 of 63

Desc

Case Number: 24-80040 (SGJ)

Debtor Name: Eiger BioPharmaceuticals, Inc.

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

SOFA Question 28: List the debtor's officers, directors, managing members, general partners, members in control, controlling shareholders, or other people in control of the debtor at the time of the filing of this case.

Name	Address	Position	% Interest
AMIT K. SACHDEV	ADDRESS ON FILE	Director	0.2%
CHRISTOPHER JAMES KURTZ	ADDRESS ON FILE	Chief Technical Officer	N/A
DAVID APELIAN	ADDRESS ON FILE	Director, Chief Executive Officer	3.7%
EVAN LOH, MD	ADDRESS ON FILE	Director	0.3%
JAMES ANDREW VOLLINS	ADDRESS ON FILE	General Counsel, Chief Compliance Officer, Corporate Secretary	0.3%
KIMBERLY LYNN SABLICH	ADDRESS ON FILE	Director	0.2%
LISA KELLY-CROSWELL	ADDRESS ON FILE	Director	N/A
THOMAS J DIETZ	ADDRESS ON FILE	Director, Chairman of the Board	0.7%
WILLIAM KACHIOFF	ADDRESS ON FILE	Chief Financial Officer	N/A

Debtor Name: Eiger BioPharmaceuticals, Inc.

Main Document Page 63 of 63

Case Number: 24-80040 (SGJ)

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

Desc

SOFA Question 29: Within 1 year before the filing of this case, did the debtor have officers, directors, managing members, general partners, members in control of the debtor, or shareholders in control of the debtor who no longer hold these positions?

Name	Address	Position	Start	End
CHRISTINE A. MURRAY	ADDRESS ON FILE	Former Director	01/07/19	03/15/24
ELDON CUNNINGHAM MAYER	ADDRESS ON FILE	Former Chief Commercial Officer	01/06/20	02/02/24
JEFFREY GLENN	ADDRESS ON FILE	Former Director	11/06/08	04/01/24